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Salivary gland carcinoma (SGC) is a rare cancer that comprises less than 5% of all 
head and neck malignancies. In Finland, approximately 60 new SGC cases appear 
annually. The diagnostics of SGCs is challenging because of their histologic 
heterogeneity. SGCs are divided into 22 entities. In some studies, 
mucoepidermoid carcinoma is the most frequent type, followed by adenoid cystic 
carcinoma (ACC).  In a Finnish nationwide study, ACC was the most common 
histologic type. ACC has three different growth patterns: cribriform, tubular, and 
solid.  
 
The clinical course of ACC is usually slow but at the same time aggressive, and the 
long-term prognosis is poor. Perineural invasion is common, and locoregional and 
distant metastases are relatively usual. The treatment of ACC includes surgery, 
with its extent depending on the stage and location of the tumor, and post-
operative radiotherapy (RT) in some cases. Chemoradiotherapy (CRT) may be 
used in patients with advanced, recurrent, or metastatic disease, but the impact 
on survival is modest. The prognosis has great diversity. The location of the tumor, 
histology, margin status, N class and presence of distant metastases are known 
factors affecting survival. Despite local aggressive therapy, over half of the patients 
will have disease recurrence. Distant metastases, the lungs being the most 
frequent site, are more common than locoregional recurrences. 
 
In this thesis study, the clinical data and treatment outcome of major and minor 
salivary gland ACC were retrieved for the time periods 1974–2009 and 1974–
2012, respectively, in the Helsinki University Hospital district area. This cohort 
included 54 major salivary gland adenoid cystic carcinoma (MaACC) patients and 
68 minor salivary gland carcinoma ACC (MiACC) patients. Most (96% of MaACC 
and 94% of MiACC) patients were treated with curative intent. Local or distant 
disease recurrence appeared in 62% of MaACC and 52% of MiACC patients during 
follow up. Recurrence was local in 35% (MaACC) and 30% (MiACC) of the 
patients, and regional in 8% (MaACC) and 13% (MiACC) of the patients. Distant 
metastases appeared in 50% (MaACC) and 34% (MiACC) of the patients. Except 
for three patients, distant metastases appeared within 10 years after diagnosis. For 
patients treated with curative intent, the 5-year overall survival (OS) and disease-
specific survival (DSS) rates were, respectively, 69% and 71% (MaACC) and 70% 
and 79% (MiACC). The 10-year OS and DSS rates were, respectively, 54% and 62% 
(MaACC) and 42% and 52% (MiACC), showing a poorer long-term prognosis for 
MiACC patients. In our study of MiACC, patients with stage I disease had 
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significantly better survival compared with patients with other disease stages. Our 
results indicate that stage II MiACC should be considered as a truly advanced 
disease needing aggressive treatment. In addition, prolonged follow up with 
imaging should be considered for ACC, as most distant metastases appear within 
10 years.  
 
Toll-like receptors (TLRs) are pattern-recognition receptors participating in 
immunological first-line host defense, particularly in inflammatory responses 
against exogenous pathogens. TLRs also have a role in innate immunity and are 
expressed in different cancers. They are thought to have both tumor-progressing 
and tumor-inhibiting effects. In SGCs, their role remains undetermined. In this 
study, the expression of TLR5 and 7 in MaACC was investigated. Thirty-four 
primary tumor samples and six metastases were available for 
immunohistochemistry. Both TLRs were expressed in both primary tumors and 
in metastases. Expression was very heterogeneous, and positivity and expression 
patterns varied within the same tumor. It was found that low TLR5 and 7 
expression, respectively, correlated with male gender and a solid growth pattern. 
A solid growth pattern is known to have a worse prognosis based on many other 
studies. No correlation was found between survival and either of these TLRs.  
 
Second primary cancers (SPCs) are a cause of significant mortality after many 
cancer types. They may be treatment-related as well as caused by the influence of 
lifestyle factors, environmental exposures, syndromes, genetic factors, or a 
combination of aforementioned. In this study, the risk of MaACC patients 
developing SPC during their lifetime was investigated. Finnish Cancer Registry 
data from 1953–2014 were used. Altogether, 1727 MaACCs occurred during this 
time period and 222 SPCs were detected. MaACC patients had a 43% higher risk 
for SPC compared with the cancer risk of the general population. The risk was 
most elevated for thyroid cancer, but the risk for melanoma of the skin, other skin 
cancers, breast cancer, cancer of the respiratory organs, and cancer of the male 
genital organs was also significantly higher. The SPC risk was higher during the 
first years after SGC diagnosis, remained the same as that of the general 
population between 5 and 10 years after diagnosis, and then started to elevate 
again, being highest after 20 years of follow up. Based on our findings, a prolonged 






SUMMARY IN FINNISH 
Sylkirauhassyöpä on harvinainen syöpä, joka kattaa alle 5 % kaikista pään ja 
kaulan alueen pahanlaatuisista kasvaimista. Suomessa todetaan vuosittain noin 
60 uutta sylkirauhassyöpää. Näiden kasvainten diagnostiikka on haastavaa niiden 
histologisen monimuotoisuuden vuoksi. Sylkirauhassyövät jaetaan 22 
histologiseen alatyyppiin. Joissain tutkimuksissa mukoepidermoidi karsinooma 
on tavallisin alatyyppi ja adenokystinen karsinooma (engl. adenoid cystic 
carcinoma, ACC) seuraavaksi yleisin. Suomalaisessa maanlaajuisessa 
tutkimuksessa ACC oli tavallisin histologinen alatyyppi. ACC:llä on kolme erilaista 
kasvutapaa: kribriforminen, tubulaarinen ja solidi. 
 
ACC:n kliininen eteneminen on yleensä hidas, mutta samaan aikaan 
aggressiivinen ja pitkän ajan ennuste on huono. Perineuraalinen invaasio on 
yleistä ja paikallinen uusiutuminen, kaulaetäpesäkkeet sekä kaukoetäpesäkkeet 
ovat kohtalaisen tavallisia. ACC:n ensisijainen hoitomuoto on kirurgia, jonka 
laajuuden määrittää kasvaimen luokitus ja sijainti, sekä leikkauksen jälkeinen 
sädehoito tietyissä tapauksissa. Kemosädehoitoa voidaan käyttää potilaille, joiden 
syöpä on pitkälle edennyt tai levinnyt, mutta sen vaikutus eloonjäämiseen on 
vaatimaton. Ennuste vaihtelee paljon. Kasvaimen sijainti, histologia, 
leikkausmarginaali, paikalliset- ja kaukoetäpesäkkeet ovat tiedettyjä 
ennusteeseen vaikuttavia tekijöitä. Paikallisesta aggressiivisesta hoidosta 
huolimatta tauti uusiutuu puolella potilaista. Kaukoetäpesäkkeet ovat 
tavallisimpia ja keuhkot ovat niiden yleisin sijainti.  
 
Väitöskirjassa selvitettiin Helsingin yliopistollisessa sairaalassa vuosina 1974-
2009 hoidettujen pienten sylkirauhasten ja vuosina 1974-2012 hoidettujen 
suurten sylkirauhasten ACC-potilaiden kliiniset piirteet, hoito ja ennuste. Aineisto 
koostui 54 potilaasta jolla oli suurten sylkirauhasten syöpä ja 68 potilaasta jolla 
oli pienten sylkirauhasten syöpä. Suurimman osan (96 % pienten ja 94 % suurten 
sylkirauhasten syövistä) hoitotavoite oli kuratiivinen. Noin kahdelle kolmasosalle 
(62 %) suurten sylkirauhasten ja 48 % pienten sylkirauhasten syöpäpotilaista tuli 
seurannassa paikallinen uusiutuma, kaulaetäpesäke tai kaukoetäpesäke. 
Uusiutuma oli paikallinen 35 % potilaista suurten sylkirauhasten syövissä ja 30 % 
potilaista pienten sylkirauhasten syövissä. Kaulaetäpesäkkeitä ilmaantui 8 % 
suurten ja 13 % pienten sylkirauhasten syöpäpotilaalle. Suurten sylkirauhasten 
syövissä kaukoetäpesäkkeitä ilmaantui 50 % potilaista ja pienten sylkirauhasten 
syövissä 34 % potilaista. Kolmea potilasta lukuun ottamatta kaukoetäpesäkkeet 
ilmaantuivat 10 vuoden sisällä diagnoosista. Kuratiivisesti hoidettujen potilaiden 
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5 vuoden kokonaiseloonjääminen oli 69 % suurten sylkirauhasten syövissä ja 70 % 
pienten sylkirauhasten syövissä ja 5 vuoden tautikohtainen eloonjääminen oli 
71 % suurten ja 79 % pienten sylkirauhasten syövissä. Vastaavasti 10 vuoden 
kokonaiseloonjääminen oli 54 % suurten ja 42 % pienten sylkirauhasten syövissä 
ja tautikohtainen eloonjääminen 62 % suurten ja 52 % pienten sylkirauhasten 
syövissä. Pienten sylkirauhassyöpien pitkäaikaisennuste näyttää 
tutkimuksessamme olevan huonompi verrattuna suurten sylkirauhasten syöpiin. 
 
Pienten sylkirauhasten syövissä tutkimuksemme mukaan potilaiden, joilla oli 
TNM-luokituksen mukainen 1. levinneisyysasteen syöpä, ennuste oli 
merkittävästi parempi kuin niillä potilailla, joilla oli jonkin muun 
levinneisyysasteen syöpä. Tulostemme mukaan pienten sylkirauhasten 2. 
levinneisyysasteen syöpää tulisi pitää merkittävästi edenneenä syöpänä ja hoito 
tulisi näin ollen olla aggressiivinen. Lisäksi on syytä harkita pidennettyä 
kuvantamisseurantaa, koska suurin osa ACC:n kaukoetäpesäkkeistä ilmaantui 10 
vuoden sisällä.  
 
Tollin kaltaiset reseptorit (engl. toll-like receptors, TLRs) ovat proteiineja, jotka 
osallistuvat elimistön ensivaiheen puolustusreaktioon erityisesti tunnistamalla 
elimistölle vieraita rakenteita tulehduksellisissa reaktiossa. TLR:t säätelevät myös 
luontaista immuniteettia ja niiden on todettu ilmenevän myös eräissä syövissä. 
TLR:lla ajatellaan olevan sekä syöpää edistäviä että syöpää hidastavia vaikutuksia, 
mutta niiden rooli sylkirauhassyövissä on vielä epäselvä. Tässä väitöskirjassa 
tutkittiin TLR:ien 5 ja 7 esiintymistä suurten sylkirauhasten ACC:ssä. 
Immunohistokemiallisiin värjäyksiin oli käytettävissä 34 näytettä 
emokasvaimista ja kuusi etäpesäkkeistä. Molemmat TLR:t esiintyivät sekä 
alkuvaiheen kasvainnäytteissä että etäpesäkenäytteissä. Esiintyminen oli hyvin 
monimuotoista ja esiintymisvoimakkuus sekä jakautuminen kudoksessa 
vaihtelivat samassa kasvainnäytteessä. Vähäinen TLR5:n esiintyminen liittyi 
miessukupuoleen ja matala TLR7:n esiintyminen solidiin kasvutapaan. Solidin 
kasvutavan on osoitettu useissa tutkimuksissa liittyvän huonompaan 
ennusteeseen. Kummallakaan TLR:lla ei havaittu olevan yhteyttä ennusteeseen.  
 
Ensimmäisen syövän jälkeen ilmaantuva uusi syöpä on merkittävä kuolleisuuden 
aiheuttaja useiden syöpien kohdalla. Uudet syövät voivat ilmaantua hoidon 
seurauksena tai niiden syntyyn voivat vaikuttaa elintavat, elinympäristö, 
oireyhtymät, geneettiset tekijät sekä näiden tekijöiden yhteisvaikutukset. 
Väitöskirjassa selvitettiin suurten sylkirauhasten syöpään sairastuneiden 
potilaiden riskiä sairastua uuteen syöpään pitkän seurannan aikana. Käytössä oli 
Suomen syöpärekisterin tilastot vuosilta 1953-2014, joissa suurten sylkirauhasten 
syöpiä oli 1727 potilaalla ja näistä 222 oli todettu uusi syöpä. Suurten 
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sylkirauhasten syöpäpotilailla oli 43 % korkeampi riski sairastua uuteen syöpään 
verrattuna normaaliväestön riskiin sairastua ensimmäiseen syöpään. Suurin riski 
oli sairastua kilpirauhassyöpään, mutta riski sairastua melanoomaan, muihin 
ihosyöpiin, rintasyöpään, hengityselinten syöpään tai miesten sukupuolielinten 
syöpään oli myös merkittävästi suurentunut. Riski sairastua uuteen syöpään oli 
korkeampi ensimmäisinä vuosina sylkirauhassyöpädiagnoosin jälkeen, yhtä suuri 
kun normaaliväestön riski 5 ja 10 vuoden välillä, jonka jälkeen se jälleen nousi 
ollen korkein 20 vuoden seurannan jälkeen. Löydöstemme mukaan pidennettyä 








Salivary gland cancer is an uncommon disease comprising approximately 3–5% 
of all head and neck malignancies and approximately 0.5% of all cancers 1. In this 
thesis, the term salivary gland carcinoma (SGC) is systemically used because 
practically all salivary gland cancers are carcinomas, i.e. epithelial in origin. In the 
Finnish population with 5.5 million inhabitants, the annual incidence of SGCs is 
0.6–0.7 per 100,000 persons 2.  
 
Most SGCs are located in the parotid gland (59–81%), followed by the 
submandibular gland (6–21%), and the minor salivary glands (7–22%). For 
unknown reasons, tumors of the sublingual glands are rare (<1%). 3, 4 The ratio of 
benign to malignant tumors varies between sites. In the parotid gland, 15–31% of 
tumors are malignant, while submandibular gland and minor salivary gland 
tumors are malignant in 40–60% and 40–90% of cases, respectively. Most 
(approximately 90%) sublingual tumors are malignant. 4, 5 The etiology of SGC is 
still largely unknown. Prior radiotherapy (RT) and ionizing radiation have 
associated with an increased incidence of SGC in several studies 6-8. 
 
SGCs are extremely heterogeneous histologically and have a great diversity of 
morphological features in both cells and tissues 9. SGCs are divided into 22 
histologic categories according to the latest WHO classification 10. 
Mucoepidermoid carcinoma is usually noted as the most common type 4. In a 
Finnish series between 1991 and 1996, adenoid cystic carcinoma (ACC) was the 
most common histologic subtype, followed by mucoepidermoid carcinoma and 
acinic cell carcinoma 11. ACC has three different growth patterns. Cribriform is the 
most common, followed by tubular and solid. Solid is the rarest and the most 
aggressive type. 9, 12 
 
ACC accounts for approximately 22–28% of all SGCs 11, 13, 14. There is a wide age 
distribution, with a peak incidence during the fifth and sixth decades 15, 16. ACC 
most often occurs in minor salivary glands, with the palate being the most 
common location 15, 17, 18. The most common symptom of ACC is a slowly growing 
mass followed by pain caused by perineural invasion (typical of ACC). However, 
symptoms vary depending on the location. In parotid tumors, facial nerve palsy 
may occur, while in minor salivary glands, the primary symptoms typically include 





The treatment of ACC consists of surgery followed by RT in selected cases. 
Chemoradiotherapy (CRT) is mainly used in advanced, recurrent, or metastatic 
disease, and there is some evidence that it improves local control 19, 20. Treatment 
options for patients with metastatic disease are observation and supportive care, 
palliative systemic therapy, or inclusion in clinical trials 15. In selected cases, 
surgical resection of pulmonary metastases may be beneficial 21. ACC has a high 
metastatic rate and poor long-term prognosis. The main factors impacting on 
survival are tumor location, histology, the presence of neck and distant 
metastases, and the surgical margin status 22, 23. 
 
New knowledge on the molecular pathogenesis and on molecular markers is 
important to identify prognostic markers and to develop alternative treatment 
modalities. Toll-like receptors (TLRs) have been studied in different cancers, as 
they are associated with tumor progression and also have tumor growth-inhibiting 
effects 24. TLRs in ACC have not previously been studied. 
 
Overall cancer survival has increased. In Finland, the 5-year relative cancer 
survival rate was 16% in men and 25% in women in 1961–63, while the respective 
figures were 34% and 46% in 1982–1984, and 66% and 69% in 2012–2014 
(www.cancer.fi). Higher cancer survival and the fact that the population is aging 
have led to the increased detection of second primary cancers (SPCs) 25.  
 
The present study aimed to determine the incidence and long-term outcome of 
both major and minor salivary gland ACC (MaACC and MiACC, respectively) in a 
population-based study in the Helsinki University Hospital district area. In 
addition, the objective was to assess TLR5 and 7 as potential prognostic markers 
in MaACC. The study also aimed to define the SPC risk of major SGC (MaSGS) 












2. REVIEW OF THE LITERATURE 
2.1 SALIVARY GLAND CARCINOMA (SGC) 
2.1.1 ANATOMY AND MORPHOLOGY OF THE SALIVARY GLANDS 
 
The salivary glands are divided into major and minor glands. The major salivary 
glands include three paired glands, the parotid, submandibular, and sublingual 
glands. The minor salivary glands consist of 600 to 1000 glands distributed 
throughout the mouth, oropharynx, upper respiratory tract, sinonasal tract, and 
sinuses. 26, 27 The salivary glands have secretory acini and secrete saliva, which can 
be serous, mucous, or mixed. The parotid duct, or Stensen’s duct, secretes almost 
completely serous saliva into the oral cavity. Within the parotid gland, there may 
be one or up to more than 20 lymph nodes, mainly in the superficial lobe of the 
gland. The weight of the parotid gland is 15–30 g, while the submandibular gland 
weighs approximately 7–16 g. Saliva produced by the submandibular gland is 
mostly serous, but also a mixture of mucous and serous. The main secretorial 
submandibular duct is called Wharton’s duct, which opens in the floor of the 
mouth. The smallest major salivary gland, the sublingual gland, weighs 
approximately 2–4 g and secretes via several ducts into the floor of the mouth or 
into Bartholini’s duct, which then leads to Wharton’s duct. Saliva produced by the 
sublingual gland is mostly of the mucous 
type. 26, 27 Figure 1 illustrates the location and 
secretorial ducts of the major salivary glands. 
The minor salivary glands are either mucous 
or seromucous. Their size varies from 1–5 
mm. 26, 27 The minor salivary glands located 
in the bronchi, nasal cavity, and larynx 
secrete mucus instead of saliva, but are still 
often classified as minor salivary glands, as 
they mimic the morphology and function of 
the glands located in the oral cavity 9.  
 
 
Figure 1.  
Location and secretorial ducts of the major  
salivary glands. Courtesy of Dr Seppo Piirainen. 
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2.1.2 EPIDEMIOLOGY OF AND RISK FACTORS FOR SGC  
 
SGCs represent approximately 0.5% of all malignancies and 3–5% of all head and 
neck malignancies 1. There are approximately 60 new SGC cases in Finland 
annually. According to the FCR, the corresponding age-adjusted incidence rates 
between the years 2010–2014 were 0.6 for females and 0.7 for males per 100,000 
person-years (www.cancer.fi). This is similar to other Nordic countries 2. Inuits in 
Greenland, Northwestern Canada, and Alaska have a high incidence of SGC. The 
age-standardized incidence rates between the years 1969–1988 were 6.0 for 
females and 3.7 for males per 100,000 person-years. 28 The risk remained high 
after immigration, which supports the idea of important genetic or early-acting 
environmental factors in the etiology 29. 
 
There are few known risk factors for SGCs. Exposure to ionizing radiation and 
prior RT treatment are related to an increased incidence of SGC, especially for 
mucoepidermoid carcinoma 6-8. In a case-control study with 64 SGC patients, 
Spitz et al. 8 also demonstrated that heavy alcohol consumption, hair dye use, and 
higher education among women are associated with SGCs. In another study with 
498 MaSGC patients, these authors showed that an agricultural occupation and 
previous primary cancer, especially nonmelanoma skin cancer in men, is related 
to an excess SGC risk 30.  
 
Lymphoepithelial SGC represents around 1% of SGCs but covers most of the Inuit 
SGCs. Lymphoepithelial SGC has histological similarities with nasopharyngeal 
cancer. 26, 28, 31, 32 Epstein-Barr virus (EBV) infection is associated with both 
nasopharyngeal and lymphoepithelial cancer 33. EBV, however, seems not to have 
a role in other SGC types 34. Patients with Acquired Immunodeficiency Syndrome 
have an increased risk of lymphoepithelial SGC, which indicates that 
immunosuppression and oncogenic viral infection might have etiological 
importance 32. 
 
Most SGCs are located in the parotid gland (59–81%), followed by the 
submandibular gland (6–21%) and minor salivary glands (7–22%) 3. Of all parotid 
gland lesions, approximately 15–31% are malignant, whereas in submandibular 
glands and minor salivary glands, the corresponding figures vary between 40–
60% and 40–90%, respectively 5. In a recent Finnish series of 83 submandibular 
tumors, 30% were malignant 35.  
 
SGCs are divided into 22 histological subtypes according to the 2017 WHO 
classification (presented in Table 1). In contrast to the 24 categories of the 2005 
WHO classification, the new WHO classification has 22 SGC categories, including 
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three subentities in the category for poorly differentiated carcinoma. One new 
SGC type, secretory carcinoma (previously called mammary analogue secretory 
carcinoma), was added to the latest classification. In addition, one cancer type 
with uncertain malignant potential, sialoblastoma, is now included in the new 
classification. 10 Malignant tumors of the salivary glands are staged according to 
the tumor, node, metastasis (TNM) classification updated by the UICC (presented 
in Table 2) 36. 
 
 
Table 1. WHO histological classification of malignant epithelial salivary gland tumors 




Adenoid cystic carcinoma 
Acinic cell carcinoma 
Polymorphous adenocarcinoma 
Clear cell carcinoma 
Basal cell adenocarcinoma 
Intraductal carcinoma 
Adenocarcinoma, not otherwise specified 
Salivary duct carcinoma 
Myoepithelial carcinoma 
Epithelial-myoepithelial carcinoma  




Poorly differentiated carcinoma 
Undifferentiated carcinoma 
Large cell neuroendocrine carcinoma 
Small cell neuroendocrine carcinoma 
Lymphoepithelial carcinoma 
Squamous cell carcinoma 
Oncocytic carcinoma 
 






Table 2. TNM classification of malignant tumors of the major salivary glands 




Tx   Primary tumor cannot be assessed  
T0   No evidence of primary tumor  
T1   ≤2 cm, no extraparenchymal extension  
T2   >2 cm, but ≤4 cm, no extraparenchymal extension  
T3   >4 cm, and/or extraparenchymal extension  
T4a   Invasion of skin, mandible, ear canal, or facial nerve  
T4b   Invasion of base of skull, pterygoid plates, or encloses 
  carotid artery  
 
N-Regional lymph nodes 
Nx  Cervical nodes cannot be assessed  
N0   No cervical nodes  
N1   One ipsilateral metastasis ≤3 cm  
N2a   One ipsilateral metastasis >3 cm, but ≤6 cm, no 
extranodal extension  
N2b   Multiple ipsilateral metastases, all ≤6 cm, no extranodal 
extension  
N2c   Bilateral or contralateral metastases, all ≤6 cm, no 
extranodal extension  
N3a   Metastasis >6 cm, no extranodal extension  
N3b  Metastasis in single or multiple lymph nodes 
   with clinical extranodal extension 
 
M-Distant metastasis 
M0   No distant metastasis  
M1  Distant metastasis  
 
Stage grouping 
Stage I   T1N0M0  
Stage II   T2N0M0  
Stage III   T3N0M0  
  T1-3N1M0  
Stage IVA  T1-3N2M0  
  T4aN0-2M0  
Stage IVB   T4b, any N, M0 
  Any T, N3, M0  





2.1.5 DIAGNOSIS OF SGC 
 
Painless swelling or palpable resistance of the salivary gland site is the most 
common symptom in SGC patients 13, 37. Pain is also fairly often experienced; pain 
was reported by half of the patients in a Finnish series 37. Patients with minor SGC 
have different symptoms depending on the site and size of the tumor. These 
symptoms include painless swelling (due to mouth tumors) and nasal obstruction 
(due to tumors originating from the sinus area). 38 Strong indicators of malignancy 
include a rapid increase in the size of the mass, local soft tissue invasion, facial 
nerve or other neuropathy, and the presence of abnormal regional lymph nodes 13, 
39. Electromyography can be used preoperatively to examine the function of the 
facial nerve more precisely than in clinical examination 40. Symptom duration 
varies from less than a month to up to 10 years 13, 37. 
 
Patients with SGCs must undergo a distinct clinical head and neck examination. 
Cranial nerve function must be assessed. Imaging modality options include 
ultrasound with or without fine needle aspiration biopsy (FNAB), computed 
tomography (CT), and magnetic resonance imaging (MRI). FNAB has a specificity 
of 98% (95% CI: 97–98%) and a sensitivity of 78% (95% CI: 74–82%) in 
differentiating malignant and benign parotid gland lesions 41. In a Finnish series 
of 47 malignant salivary gland tumors, the sensitivity and specificity of FNA was 
55% and 92%, respectively, in differentiating malignant and benign lesions 42. 
With submandibular tumors, the sensitivity and specificity were 90% and 100%, 
respectively 35. Analyses of histological fragments found in FNAB and the use of 
immunohistochemistry in challenging cases are valuable tools in SGC diagnosis. 
This method was crucial for the diagnosis in 44% of examined SGCs in a Finnish 
study 43. Open biopsy is not recommended due to the risk of nerve damage and 
seeding of tumor cells 4. 
 
Frozen sections (FS) can be used during surgery if the diagnosis is preoperatively 
unclear. FS is used to differentiate between benign and malignant tumors or low- 
or high-grade malignancies, to determine the extent of the tumor as well as the 
excision margins, and to assess loco-regional lymph node participation 4. FS has 
better sensitivity and specificity than FNAB. In a series of 138 parotid tumors, 
Fakhry et al. 44 determined that the sensitivity and specificity of FS was 98% and 
80%, respectively. However, parotid tumors are often not homogeneous and the 
FS diagnosis can therefore be misleading. The final clinical decision must be made 
after careful examination of the whole tumor specimen. 44 The experience of the 
pathologist is important when considering the diagnosis of SGCs. Determining the 
correct diagnosis is challenging due to the complexity of the classification and the 




Ultrasound may be used to detect superficial lesions and to show regional nodes. 
It is very cost-effective, but it may not always assess deeper structures. CT and 
MRI reveal the exact location and extent of the tumor. They can also show the 
perineural extension of the tumor. MRI more accurately shows invasion in soft 
tissues, diffuse growth patterns, perineural invasion, and lymphadenopathy. MRI 
is usually the modality of choice. 27, 46 Diffusion-weighted MRI (DWI) is used both 
in primary diagnosis and in follow up. DWI is especially useful in differentiating 
pleomorphic adenoma and lymphomas from SGC. 47  
 
In a study by Razfar et al. 48, PET (positron emission tomography) -CT displayed 
a sensitivity of 74%, a specificity of 100%, positive predictive value of 100%, and a 
negative predictive value of 62% in SGCs. PET-CT is accurate in initial staging and 
detecting metastatic disease, and may assist in deciding between curative and 
palliative treatment 48. The most important application of PET-CT is in follow-up 
imaging after treatment. 
2.1.6 TREATMENT OF SGC 
 
The standard treatment for SGCs is surgery with or without RT. However, 
treatment must be individualized for each patient 49. When the tumor is located in 
the superficial lobe of the parotis, superficial parotidectomy (removal of all 
parenchyma superficial to the facial nerve) is the treatment of choice. In partial 
parotidectomy, only the tumor and surrounding glandular cuff is removed. When 
the deep parotid lobe is involved, total parotidectomy (removal of all parotid 
parenchyma) is considered. If the facial nerve must be sacrificed, the procedure is 
called radical parotidectomy. If the surgery extends to the skin, mastoid, 
mandible, masticatory muscles, or infratemporal fossa, it is called extended 
radical parotidectomy. 
 
Stage III and IV parotid tumors often require at least total parotidectomy. 
However, it is debatable whether total parotidectomy should be performed, even 
in low-stage tumors, as both the superficial and deep parotid lobes contain lymph 
nodes and thus have direct contact with the cervical lymphatic field. 50 
 
The principal goal is that if facial nerve function is normal before operation, it 
should not be sacrificed. However, if the nerve is preoperatively paralyzed, 
adherent, or surrounded by tumor, it must be sacrificed. If possible, immediate 
surgical reconstruction should be performed to achieve the best possible 
functional outcome. The greater auricular nerve is commonly used for cable 
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grafting, as it is easily accessed and has a similar, monofascicular structure to the 
facial nerve. 50-52 The sural nerve is also often used 53, 54. 
 
For submandibular tumors, in addition to removing the whole gland, clearance of 
the submandibular triangle (including level I nodes) is recommended. Depending 
on the tumor type, resection of the close structures (lingual and hypoglossal 
nerves and digastric, mylohyoid, hyoglossus, and stylohyoid muscles) may be 
required. 50, 51 In sublingual cancer surgery, the whole gland must be removed. 
Due to gland location and missing of the encapsulating cervical fascia, removal of 
the floor of the mouth mucosa, lingual nerve, or part of mandible or 
submandibular gland is sometimes necessary. 50, 51 
 
In minor SGCs, wide local resection with clear tumor margins is the treatment of 
choice. Resectability is planned preoperatively based on location, stage, and 
histology. 55 Surgery can often influence speech, swallowing, and velopharyngeal 
competence, as common locations include the palate and base of the tongue 51.  
 
Neck dissection should be performed when there are clinically apparent 
metastases or when the primary tumor has a significant risk of developing occult 
metastases. However, it is debatable how to treat a clinically negative neck, as 
detecting the true frequency of positive lymph nodes is challenging. 56 
 
Postoperative RT is recommended in patients with high risk factors such as T3 or 
T4 tumors, incomplete or close resection margins, high grade, vascular or 
perineural invasion, positive lymph nodes, as well as in the case of recurrent 
disease or if the tumor has invaded skin, bone, nerve, or extra-capsular tissue 57, 
58. Surgery combined with postoperative RT compared with surgery alone is 
superior in terms of 5- and 10-year local control in these cases. However, the role 
of adjuvant RT in T1 and T2 patients with clear surgical margins has not been 
confirmed. Primary RT is mainly considered for patients with inoperable disease, 
unresectable tumor, or for those who refuse surgery. 57 Chemotherapy is mostly 
reserved for palliative treatment in cases of symptomatic recurrent disease where 
further surgery or RT does not play a role 57. 
2.1.7 PROGNOSIS OF SGC 
 
The prognosis depends on the localization of the gland, stage, histology, grade, 
disease extension, facial nerve paralysis, and lymph node status 49, 51. The stage 
appears to be superior compared with grading in prognostication 49. Patient age 
and positive surgical margins are important factors for locoregional control in the 
 
 22
management of parotid malignancies 49. Distant metastases are most commonly 
found in the lungs (80%), followed by bone (15%), liver, and other sites (5%). 
Distant metastases are the primary cause of death. The metastasis rate is highest 
(50%) in ACC, adenocarcinoma NOS, carcinoma ex-mixed tumor, small-cell 
carcinoma, and ductal carcinoma. 49 In a Finnish nationwide series from 1991 to 
1996, the 10-year disease-specific survival (DSS) for SGC patients was 64% 11, and 
the 5-year relative survival for SGC patients diagnosed in Finland between 2010–
2014 was 61% (95% CI: 53–70) 2. In a German study on 63 SGC patients, the 5-
year OS and DFS were 63 and 58%, respectively 59. 
2.2 SALIVARY GLAND ADENOID CYSTIC CARCINOMA (ACC) 
2.2.1 EPIDEMIOLOGY AND CLINICAL FEATURES OF ACC 
 
ACC comprises approximately 22% of all SGCs 13. In Finnish material covering the 
years 1991–1996, there were 65 ACCs, which formed 27% of all SGC malignancies 
11. In Danish material for the years 1990–2005, altogether 240 ACCs were 
identified. This series represented 28% of all SGCs during this time period and 
corresponded to an incidence of 3/1,000,000/year. 14 
 
ACCs are most commonly located in the minor salivary glands. The most frequent 
location is the palate, followed by the paranasal sinuses and other oral cavity sites 
17, 18, 60. Spiro 13 reported the location distribution as follows: 19% parotid, 16% 
submandibular, and 65% minor salivary glands. In the Danish population, 32% of 
the tumors were parotid, 23% were submandibular, 4% were sublingual, and 40% 
were of minor salivary gland origin 14. In a Finnish single-institution series of 
submandibular tumors, ACC was the most common histology and accounted for 
68% of cases 35.  
 
ACC can also appear in any site where mucous glands exist. Sites other than the 
head and neck include the breasts, vulva, esophagus, cervix, bronchi, and skin 61-
64. ACC is extremely rare in these locations. Unlike in salivary glands, ACC has a 
very good prognosis and a low metastasis rate in the breasts 65. 
 
ACC most often occurs in the fifth and sixth decades, but all age groups are 
represented 16, 60. It is extremely rare in children. Female predominance has been 
reported by many studies, but some have also shown male predominance or no 




2.2.2 HISTOPATHOLOGY OF ACC  
 
ACC consists of two principal cell types: ductal and modified myoepithelial cells 
that usually have hyperchromatic, angular nuclei and often a clear cytoplasm 26. 
ACC is divided histologically into cribriform, tubular, and solid growth patterns 
(Figure 2). The cribriform pattern is the most common. The solid pattern is the 
rarest and has the poorest prognosis. The solid pattern is associated with a high 
frequency of distant metastases and thus with a high stage. 17, 26, 67 The tubular 
growth pattern has the best prognosis. Tumors often have different growth 
patterns, and the dominant pattern determines their classification. 46 Perineural 
invasion is common, even among early-stage tumors 17, 26.  
 
ACC is often graded histopathologically into three grades according to its growth 
pattern. Grade I includes no solid pattern, grade II includes less than 30% solid 
pattern, and grade III more than 30% solid pattern 68. High-grade transformation 
(HGT) is a rare phenomenon, involving ACC mostly in sinonasal and palatal minor 
salivary glands and in the submandibular gland. It is histologically a component 
of conventional ACC and another distinct anaplastic cell population that lacks 
ductal and myoepithelial dedifferentiation. While these components can be 
separate, transitional zones exist. HGT ACC appears to have the poorest prognosis 




The molecular pathogenesis of ACC is poorly understood. Studies on 
chromosomal translocations have been performed to find molecular diagnostic 
tools as well as target-specific therapies. The most important finding so far was 
reported by Persson et al. 70, who observed a frequent t(6;9) (q22-23;p23-24) 
translocation in ACC that regularly results in a fusion of the myeblastosis (MYB) 
oncogene with the transcription factor I/B (NFIB). This fusion oncogene is highly 
overexpressed and is specific to ACC 71. A novel finding by Mitani et al. 72 was an 
MYBL1-NFIB gene fusion resulting in a t(8;9) translocation and several 
rearrangements in the MYBL1 gene in 35% of t(6;9)-negative ACCs.  
 
C-kit is a tyrosine kinase receptor that is overexpressed in 90% of ACC. While it 
correlates with tumor grade in ACC, the exact mechanism is still unclear 73, 74. An 
increase in MIB-1 antibody expression is associated with more aggressive tumor 
behavior and a poor prognosis 75. Neurotrophin-3 receptor TrkC/NTRK3 is also 
found to be expressed in ACC, suggesting the existence of an autocrine signaling 
loop in these tumors 76. Immune checkpoint inhibitors, for example the role of PD-
1 inhibition, have also been investigated in ACC 77 
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Ho et al. 78 found a low exonic somatic mutation rate and high mutational diversity 
in their report on 60 ACC tumor/normal pairs. Potential driver mutations were 
identified, and include those in PIK3CA, TP53, PTEN, SsMARCA2, KDM6A, and 
CREBBP. These findings indicate aberrant epigenetic regulations in ACC 
oncogenesis 78. 
 
Figure 2. Different growth patterns of ACC (magnification x 20): cribriformic (A), tubular (B), and 
solid (C).  
2.2.3 DIAGNOSIS OF ACC 
 
The symptoms of ACC are dependent on the location of the tumor and do not differ 
from the SGCs in general (2.1.5). However, perineural invasion and resultant pain 
are more common findings in ACC than in other SGCs 79-81. ACC has also been 
described to grow slower than other SGCs 60, 82. The first diagnostic procedure is 
FNAB, as in other SGCs 60, 82. The imaging modalities used are in general the same 
as in other SGCs, with MRI usually being the imaging modality of choice. Figure 
3 presents an MRI of ACC of the sinonasal area extending into the orbit. 
 
Figure 3. T2-weighted coronal MR image of sinonasal ACC extending into the orbit. The bright T2 
signal is typical of ACC (A). T1-weighted contrast-enhanced axial MRI of ACC extending into the orbit 
and causing exophthalmus. The tumor has spread along the maxillary nerve through the foramen 
rotundum into the right sinus cavernosus (B). Courtesy of Dr Antti Markkola.  




2.2.4 TREATMENT OF ACC 
 
Treatment of the primary tumor  
 
The “gold-standard” treatment for ACC is radical surgical resection (including free 
margins) followed by RT. However, the treatment strategy depends on the site, 
stage, histological grade, and biological behavior of ACC. 17, 60 ACC has a distinct 
tendency to spread along the nerves and subperiosteal and perichondral areas; 
careful consideration of nerve sacrification and the liberal use of FSs are necessary 
50. Treatment protocols of parotid, submandibular, and sublingual tumors are the 
same as in SGCs in general (2.1.6). With MiACC, surgical margins are reported to 
be inadequate in 27–64% of cases; the situation is poorest in the oral cavity and 
sinonasal area 50. MiACC is often diagnosed at an advanced stage, especially in the 
sinonasal area and larynx 50, 55. The use of endoscopic transnasal surgery has been 
investigated and supported by some studies, especially in ACC of the ethmoid area 
50. 
 
Treatment of the neck 
 
In parotid ACCs, neck dissection should be performed on patients with clinical 
evidence of nodal metastases. It has been shown that neck levels I–V are affected 
in N+ parotid tumors with all histologies 83. Therefore, it is recommended to 
remove lymph nodes from all neck levels 50. Neck metastases are more common 
in the submandibular gland than in the parotis. This may be due to direct invasion 
of the tumor or affected soft tissues into adjacent nodes and perineural spread. 50, 
51, 51 It has been discussed that all except T1 submandibular carcinomas should 
warrant elective neck dissection 51. 
 
It is debatable when to perform elective neck dissection. The incidence of occult 
metastases in ACC varies between 15–44%, and such metastases are more 
common in oral cavity/oropharyngeal carcinomas than in sinonasal and MaACCs 
84. In a multicenter study by Amit et al. 85 with both major and minor ACCs 
included, the occult nodal metastasis rate was 17%. Occult metastases were mainly 
located in the ipsilateral levels I–III. No significant difference in survival was 
observed between patients who had or did not have elective neck dissection 85. 
ACC with high-grade transformation has a high lymph-node metastasis rate (43–
57% of patients), and elective neck dissection is therefore highly recommended for 








Post-operative RT is recommended if primary surgery has positive or close 
resection margins, if there is infiltration of major nerve, bone, or muscle, in the 
case of high-grade histology, paranasal sinus location, and high T and N 
classification 55, 86. There is evidence that adjuvant RT increases the survival of 
ACC patients 87, 88. In a study of ACCs by Lee et al. 88, postoperative RT resulted in 
a 9.5% and 11.6% improvement in 5-year overall survival (OS) compared with 
surgery alone for pT1-T2 and pT3-4 cancers, respectively. The survival benefit was 
23.4% for tumors with positive lymph nodes and 17.1% for positive margin status 
with combined therapy. Patients with negative margins did not have better 
survival after adjuvant RT combined with surgery alone. 88 Many centers consider 
adjuvant RT as the standard of care 12, 18. The aim is to initiate RT in four weeks 
after surgery. Intensity-modulated radiotherapy (IMRT) is the treatment of 
choice. IMRT provides better local control and has fewer side effects, as the 
surrounding structures receive less radiation. The radiation dose is usually 
between 66–70 Gy. Primary RT can be used in unresectable cases, if resection 
would cause unacceptable functional and cosmetic outcome, and in palliative care. 
86  
Gentile et al. 89 investigated proton beam therapy with or without chemotherapy 
for 14 patients with unresectable ACC of the nasopharynx with skull base 
involvement. Proton beam therapy showed a promising local control rate with 
three late local failures 89. This therapy is not currently available in Finland. 
Patients who would benefit from this modality can be sent to some of the proton 
centers in Northern Europe. When compared with IMRT only or fractionated 
stereotactic RT, raster-scanned carbon ion boost combined with IMRT led to 
better locoregional control, progression-free survival, and OS 90. CRT with 
different agents can be used in the management of high-risk tumors. There is 
some evidence that this approach improves local control. 19, 20  
 
Treatment of metastatic and recurrent ACC 
 
The current options for patients with metastatic disease are observation and 
supportive care, palliative systemic therapy, or inclusion in clinical trials 
investigating novel chemotherapeutic agents 60.  
 
The lungs are the most common location for distant metastases. However, lung 
metastases do not often appear as solitary lesions. Metastases may be relatively 
stable for months and routine thoracotomy is not advisable. 17, 91 Girelli et al. 21 
stated that lung metastasectomy should be considered as a therapeutic option to 
achieve local control when complete surgical resection is possible and when 
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pulmonary metastases appear more than 36 months after primary treatment. It is 
still not clear whether incomplete lung resection provides symptomatic benefit 21.  
 
Chemotherapy has not yet proved to be beneficial, as many ACC tumors have slow 
growth kinetics. A low response rate in metastatic disease has been shown in many 
studies, but no standard treatment modality exists. 82 Trials have included small 
populations with great heterogeneity concerning histology, the state of 
recurrence, and prior therapies. Furthermore, as ACC has a slow growth pattern, 
response assessment is difficult. Systemic therapy is mainly reserved for patients 
with symptoms, rapidly progressive disease, or both. 92  
 
Targeted therapy is under research. Several potential therapeutic targets have 
been studied in ACC. These include the tyrosine kinase inhibitors imatinib, 
gefitinib, and lapatinib, the monoclonal antibodies cetuximab and trastuzumab, 
and the proteasome inhibitor bortezomib. No real antitumor activity has been 
shown. There is evidence of disease stabilization for a few months 93. There are a 
few case reports of tamoxifen hormone therapy in recurrent ACC, where disease 
progression slowed down 94. Several clinical trials are ongoing with the aim to find 
clinically relevant antitumor activity for these and related targeted agents 82.  
2.2.5 PROGNOSIS OF ACC 
  
Despite local aggressive therapy, approximately 60% of patients will have disease 
recurrence 95. Factors that increase local recurrence rate are positive surgical 
margins, major nerve involvement, and primary tumor origin in a minor salivary 
gland 96. The local recurrence rate was 40% in a study of MiACCs 23. Clinically 
evident neck metastases at diagnosis are reported to occur in 3–16% of patients, 
depending on the site of origin and series 23, 84. 
 
Solid growth pattern, tumor size over 3 cm, primary tumor origin in the nasal 
cavity/paranasal sinuses or orbit, positive lymph nodes, age over 70 years, or local 
recurrence all increase the risk for distant metastases 12, 22, 96. The low long-term 
survival in ACC is due to frequent distant metastases and the failure to control 
them. Distant metastases are reported to appear in 35–55% of patients and to be 
more common than regional recurrences. 67, 91 In a study that only included early-
stage (T1-2/N0) ACCs, 20% of patients developed distant metastases 12. These 
metastases are thought to develop via a hematogenous route. The most common 
location is the lungs 18, 22, 60, 67, 91. Another common location is bone, and in this 
case disease progression is usually rapid 96. Other locations for distant metastases 
are the liver, skin, breasts, and rarely the brain 82. Lung metastases seem to appear 
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earlier than metastases in other sites. However, according to a study by Van der 
Wal et al. 91, patients with lung metastases die approximately a year later than 
patients with metastases in other locations. In a study by Amit et al. 22, patients 
with bone and brain metastases had the poorest outcome, with a 31% and 25% 
median 5-year survival, respectively. Patients with lung and liver metastases had 
a 66% and 84% median 5-year survival, respectively 22. 
 
ACC is thought to have a prolonged natural course, with slow growth and 
sometimes also extended survival after recurrent disease 97, 98. Survival figures are 
presented in Table 3. Five-year OS rates vary between 76–92% 14, 22, 23, 81, 87, 88, 99. 
In a Danish series of 240 ACC patients, the 15-year OS rate was 46%, and 
recurrences appeared as late as after 15 years after primary treatment 14.  
 
 
Table 3. Survival rates of patients with ACC 
 
Study, number of patients 
Survival rates (%) 
 5-year 10-year 15-year 
Bjorndal et al. 2015; n = 201 14 OS 80 58 46 
 DSS 90 75 68 
 DFS 72 60 55 
Ellington et al. 2012; n = 3026 81 OS 90 80 69 
Amit et al. 2014; n = 489 22 OS 76   
  DSS 80   
  DFS 68   
Ciccolallo et al. 2009; n = 2611 99 OS 78 65  
He et al. 2017; n = 130 (only MiACCs) 23 OS 81   
 DFS 56   
Lee et al. 2017; n = 61 88 OS 81   
  DFS 56   
Shen et al. 2012; n = 101 87 OS 92   
  DFS 63   
 
 
In several studies, perineural invasion has associated with local recurrence and 
margin involvement, but not with rate of metastasis and survival 66, 100. Other 
studies have found perineural invasion to be a prognostic factor for OS and DFS 
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23, 100, 101. In an international study by Amit et al. 22, age, site, N classification, and 
the presence of distant metastases were independent prognostic factors for OS 
and DSS and margin status was for OS. In the study by He et al. 23 on MiACC, a 
solid histologic type and positive surgical margins were independent prognostic 
markers for OS. 
 
Nomograms are statistical tools that can be used to accurately predict the outcome 
of an individual patient. They apply also multiple other variables in addition to 
TNM. 102 Ganly et al. 103 created predictive nomograms for ACC. They used an 
international database and created four different nomograms based on 438 
MaACCs. The 10-year OS nomogram had seven variables: age, gender, clinical T 
class, tumor site, margin status, pathologic N status and M status; the 
concordance index was 0.71. Other nomograms predicted the 10-year recurrence-
free probability, distant recurrence-free probability, and cancer-specific 
mortality; the concordance indices were 0.66, 0.64, and 0.70, respectively 103. 
2.3 TOLL-LIKE RECEPTORS 
2.3.1 TLRS IN IMMUNE DEFENCE AND CANCER 
 
TLRs are transmembrane pattern-recognition receptors, which participate in 
immunological first-line host defense, especially in inflammatory responses 
against different exogenous pathogens. TLRs regulate the innate and adaptive 
immunity of epithelial cells located at mucosal sites such as skin and respiratory, 
gastrointestinal, and genitourinary tracts. 104-106 TLRs recognize pathogen-
associated molecular patterns and activate immune cells and immune cascades to 
target the pathogen 24, 107. Furthermore, TLRs can recognize damage-associated 
molecular patterns released from injured and inflamed tissue 24, 108. TLR signaling 
also regulates apoptosis by expressing either antiapoptotic proteins or apoptosis 
inhibitors 24. 
 
The name ‘Toll-like receptor’ comes from their similarity to the protein encoded 
by the Drosophila Toll gene, which was identified in 1985 109. There are ten known 
TLRs in humans and 12 functional TLRs in mice. TLRs 3, 7, 8, and 9 mainly 
function intracellularly on endosome membranes and detect bacterial DNA and 
viral RNA 105, 107, 108. TLRs 1, 2, 4, 5, 6, and 10 are mainly expressed on the cell 
surface, where they recognize microbial membrane components such as 




There is a well-established connection between the development of cancer and 
chronic inflammation caused by infection, environmental agent exposure, genetic 
disease or metabolic disorders. Approximately 20% of cancers are presumed to be 
associated with chronic infection 110. Examples of this relationship include 
hepatitis B virus and hepatocellular carcinoma, Helicobacter pylori and gastric 
carcinoma, condylomata accuminata and genital cancer, Human papilloma virus 
(HPV) and oropharyngeal cancer, and polyoma virus and Merkel cell carcinoma 
111-115. 
 
In addition to providing signals crucial to the resolution of inflammation, TLRs 
also have a distinct role in cancer. They act as double-edged swords, as they 
possess both pro- and antitumor effects. 104 The role of TLRs in cancer is complex 
and under active research. TLR activation in tumor cells may promote the survival 
of these cells, as well as chemoresistance, ultimately leading to tumor progression. 
Many tumor cells or cell lines express one, or more commonly several TLRs. Each 
TLR is thought to have a particular effect on cancer, and this effect depends on 
both the receptor and tumor type. 24, 104, 105 TLRs can have antitumor effects by 
activating host immune responses. Bacterial components, such as DNA and endo- 
or exotoxins, exhibit antitumor effects partly through enhanced innate immunity. 
In immunotherapy, microbe-derived therapeutics stimulate TLR signaling and 
activate innate and adaptive immune responses. For example, OK-432, a TLR4 
agonist used as an immunotherapeutic agent in many cancers, is a penicillin-killed 
and lyophilized preparation of a low-virulence Streptococcus pyogenes strain. 104 
Mycobacterium bovis bacillus Calmette-Guerin, which is used against superficial 
bladder tumors, is also a TLR2/4 agonist 24. Targeting TLRs with TLR agonists 
might be a future weapon in the fight against cancer. However, not all TLR 
agonists and signaling pathways have antitumor activity. It is important to 
elucidate the function and regulation of each TLR in different cancers to gain more 
information on tumor progression and initiation. 24, 104 
2.3.2 TLRS IN HEAD AND NECK CANCERS  
 
Different TLRs have been studied in oral squamous cell carcinoma. TLR5 is 
expressed in oral tongue squamous cell carcinoma (OTSCC), and was shown to be 
an independent predictor of mortality and disease recurrence 116. In another study 
on early-stage OTSCC, negative or low TLR5 expression predicted poor DSS, and 
expression of TLRs 2, 4, and 9 was associated with the invasive potential of the 
tumor 117. These TLRs are suggested to have a role in both the development and 
progression of OTSCC, as they were expressed in primary and recurrent tumors, 
as well as in neck metastases 118. TLR3 is overexpressed in oral squamous cell 
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tumors with high-risk histopathological features 119. TLR2 is expressed in oral 
squamous cell cancer, and its activation leads to growth-promoting effects. 
Blocking the TLR2 receptor with a monoclonal antibody leads to the inhibition of 
tumor growth in both in vitro and in vivo studies. 120 In another study on oral 
squamous cell carcinoma, low tumor TLR7 expression and high stromal TLR7 
expression predicted a good outcome 121. Jouhi et al. 122 observed low TLR5 
expression and high TLR7 expression in p16-positive oropharyngeal squamous 
cell carcinoma (OPSCC) both in vivo and in vitro. TLR7 and 9 staining also 
correlated with HPV status in vivo 122. In addition, they showed that high TLR5 
and low TLR7 expression may be related to a poor prognosis among HPV-positive 
OPSCC patients 123. 
 
In recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), the 
TLR8 agonist motolimod combined with cetuximab was used in a Phase Ib clinical 
trial with encouraging antitumor activity 124. In addition, the TLR9 agonist IMO-
2055 was tested in combination with 5-fluorouracil, cisplatin, and cetuximab in 
similar patients as a first-line palliative treatment in a Phase Ib trial. This trial 
was, however, discontinued due to severe side effects 125.  
 
In a study on laryngeal papillomas transforming into squamous cell carcinoma, 
TLR4 expression was significantly lower in papillomas transforming into cancer 
than in papillomas without malignant transformation. In laryngeal squamous cell 
cancer, high TLR4 expression correlated with the tumor grade and the T class, and 
in this regard, possibly with tumor aggressiveness. 126 TLRs have also been 
investigated in juvenile nasopharyngeal angiofibroma, where TLR3 negativity 
correlated with a high tumor stage 127.  
2.3.3 TLRS IN SALIVARY GLAND CARCINOMAS 
 
There have only been a few studies on TLRs in SGCs. Korvala et al. 128 examined 
TLR9 expression in mucoepidermoid carcinoma. Low expression was associated 
with a high disease stage and a poor prognosis 128. In a study by Park et al. 129, 
TLR5 activation by flagellin, a TLR5 agonist, promoted tumor migration and 




2.4 SECOND PRIMARY CANCER 
2.4.1 GENERAL CONSIDERATIONS  
 
Survival after cancer treatment has significantly improved over several decades 
due to improved early detection, treatment, and supportive care. In the United 
States, 5-year relative cancer survival has increased from under 50% in 1975–1979 
to 67% in 2005–2009 (including all cancers). Survival is over 80% in childhood 
cancer. 25 The same trend is seen in Finland, where the 5-year relative cancer 
survival for men and women, respectively, was 16% and 25% in 1961–63, 34% and 
46% in 1982–1984, and 66% and 69% in 2012–2014 (www.cancer.fi). This fact, 
together with the aging population, has led to the current situation where 
approximately one out of six cancers appear among cancer survivors in the United 
States 25. In Finland during 1975–2014 (www.cancer.fi), the risk for SPCs was 
approximately 38% higher compared with the risk of developing a first cancer 
(SIR 1.38, 95% CI: 1.37-1.39).  
 
SPCs are a significant cause of death among many cancer survivors, for example 
for survivors of Hodgkin’s lymphoma 130. SPCs can be treatment-related or caused 
by the influence of lifestyle factors, environmental exposures, or syndromes. 
Combinations of different influences, such as gene–environment and treatment 
and lifestyle interactions, may also play a role. 131 For survivors of childhood 
cancer, the most likely etiologic causes are primary cancer treatments and genetic 
factors, whereas for adults, in addition to these factors, environmental and 
lifestyle factors may also be etiologic causes 132.  
 
RT, certain chemotherapy regimens, and hormone treatment have the potential 
to cause second cancers in patients. Radiation exposure has been found to 
increase the SPC risk materially in brain, thyroid, female breasts, skin, bone, and 
soft tissue cancers. A modestly increased risk is seen in cancers of the lungs, 
bladder, and gastrointestinal tract, and in myeloid leukemias. The type of tissue, 
radiation dose, and the time period over which the radiation occurred, as well as 
the time delay since exposure, all play roles in the potential risk. 133  
 
Tobacco use is one of the major risk factors for SPC. Known tobacco-related cancer 
sites for second primary cases are the lungs and upper aerodigestive tract 134. 
Smoking and alcohol consumption are estimated to account for more than 35% of 
the SPC risk 135. 
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2.4.2 SPCS IN PATIENTS WITH HEAD AND NECK CANCERS  
 
SPCs following HNSCCs most commonly express the same histology and appear 
in the upper and lower aerodigestive tract, but also in other tobacco-related sites 
136, 137. In a cohort of 190,468 head and neck cancer patients, RT did not increase 
the SPC risk, indicating that environmental and lifestyle factors play a larger role 
in these sites 138. Field cancerization, described by Slaughter in 1956 139, is often 
cited in describing the development of SPCs in squamous cell carcinoma. It is 
assumed that after the tumor is radically removed, genetically altered field could 
be the origin for a new cancer 140. 
2.4.3 SPCS IN PATIENTS WITH SALIVARY GLAND CARCINOMAS 
 
Studies on the SPC risk among SGC patients are scarce. The association between 
SGC and second primary breast cancer has been the most studied. Some studies 
have found a positive relationship between these two cancers, with standardized 
incidence ratio (SIR) values ranging from 2.3–4.8 141-144. However, other studies 
have not found an increased breast cancer risk after SGC 145, 146. In a series of 782 
SGC patients, Biggar et al. 145 detected an increased ovarian SPC risk in women 
and respiratory SPC risk in men. There have been two previous studies on MaSGC 
and SPC risk. Spitz et al. 147, 148 studied MaSGC patients from 1960–1981 and 
compared them with the general population. They found a significantly elevated 
risk of skin cancer both as an SPC as well as prior to SGC. Megwalu and Shin 146 
used a database of 15,572 MaSGC patients in the United States and found an 
elevated risk of SPCs of the oral cavity, salivary glands, thyroid, lungs, and kidney. 
The risk remained elevated even 10 years after treatment of the primary cancer. 
RT treatment increased the risk for thyroid, laryngeal and lung/bronchus cancers, 
while oral SPC was not associated with RT 146.  
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3. AIMS OF THE STUDY 
The main objective of this study was to assess the factors that determine the long-
term outcome of ACC patients. As finding new prognostic markers for these 
carcinomas is important, the intention was to clarify the role of TLR5 and 7 in 
MaACC. The aim was also to determine whether there is a risk for certain SPCs, 
because some SGC patients have long survival after treatment. Knowledge of such 
a risk could be considered in planning of the follow up for SGC patients.  
 
The specific aims of the present study were:  
 
1. To evaluate and compare the clinical and histological characteristics of both 
major and minor salivary gland ACC during the past 35 years at our department 
in order to clarify their influence on patient survival (Studies I and III). 
 
2. To examine the expression of TLR5 and 7 in major salivary gland ACC and their 
association with clinical characteristics, including survival (Study II). 
 
3. To investigate the risk of developing an SPC during a long-term follow up of 







4. MATERIALS AND METHODS  
All patients in Studies I, II, and III were diagnosed and treated at the Helsinki 
University Hospital, which is a tertiary care hospital covering an area of 
approximately 1.6 million inhabitants. In Study IV, the patient cohort consisted of 
a nationwide series in Finland (population 5.5 million).  
4.1 STUDY I 
In this study, the characteristics, treatment, and outcome of 54 MaACCs 
diagnosed between January 1974 and September 2009 in the Helsinki University 
Hospital district area were described. All patient records were reviewed and the 
tumor sample histopathology was re-evaluated by two experienced head and neck 
pathologists (Drs Jaana Hagström and Ilmo Leivo). The diagnostic criteria were 
validated according to the WHO classification (2005). Tumor staging was 
performed according to the TNM classification (UICC 2009, 7th edition). Causes 
and dates of death were retrieved from Statistics Finland. All patients had a 
minimum follow up of five years or until death. OS, DFS, and DSS were calculated 
from the last day of treatment to the last day of follow up or death (OS), to any 
sign of tumor recurrence or death (DFS), or to any sign of tumor recurrence or 
death due to disease (DSS). 
4.2 STUDY II (IMMUNOHISTOCHEMISTRY) 
For the 54 MaACC patients, 34 primary tumor samples and six metastases were 
identified. All of these samples were used for immunohistochemical evaluation. 
For the remaining 20 primary tumors, no sufficient tumor samples existed. The 
Helsinki Head and Neck Research Group has earlier studied TLR5 and 7 in 
OPSCC, yielding results on their impact on the prognosis and the viral status. 
Therefore, these same TLRs were chosen to examine their role in this non-viral 
carcinoma.  
 
Tissue samples were sliced into 4-μm sections. These sections were deparaffinized 
in xylene and rehydrated in a series of graded alcohol. The slides were heated in a 
Pretreatment Module (Lab Vision Corp., UK Ltd, UK) in Tris-HCl buffer for TLR7 
(pH 8.5) and Tris-EDTA buffer for TLR5 (pH 9.0), followed by endogenous 
 
 36
peroxidase blocking with 0.3% Dako REAL Peroxidase-Blocking Solution 
(Agilent, Santa Clara, CA, USA). For immunostaining, monoclonal mouse anti-
human antibody was used for TLR5 (1:200, IMG-664A Imgenex, Cruz 
Biotechnology, Dallas, Texas, USA) and polyclonal rabbit anti-human antibody 
was used for TLR7 (1:300, IMG-581A Imgenex). This was followed by incubation 
with Dako REAL Antibody Diluent S2022 (Agilent) and staining, which was 
visualized with Dako REAL DAB+ Chromogen (Agilent). Between each phase, 
slides were washed with PBS 0.04%-Tween20. Counterstaining was performed 
with Meyer’s hematoxylin and slide mounting with PERTEX (Histolab, Askim, 
Göteborg). The positive control was tonsillar squamous cell carcinoma tissue. 
Slides in which the primary antibody was replaced with PBS served as negative 
controls. 
 
 Immunoscoring (Study II) 
 
The slides were scored by two independent researchers (J.H. and K.H.) who were 
blinded to the clinical data. The location (cytoplasm, nucleus, or cell membrane) 
of TLR5 and 7 expression in the specimen was determined, and the percentage of 
positively-stained cells was then estimated. Immunoscores were grouped as 
follows: 0 for 0–10% (negative or very mild), 1 for 11–40% (mild), 2 for 41–70% 
(moderate), and 3 for 71–100% positivity (strong). Normal salivary gland tissue, 
which was found in most slides, was used to validate the expression in normal 
tissue.  
4.3 STUDY III 
The characteristics, treatment, and outcome of 68 patients with MiACC diagnosed 
between 1974 and 2012 were described. Out of the records of 86 patients, the 
diagnosis was correct and medical records were available for 68 patients. The 
results were compared with those of MaACC. Histopathological diagnoses were 
confirmed and updated according to the WHO classification (2005) by an 
experienced head and neck pathologist (J.H.). Statistics Finland provided causes 
and dates of death. OS, DSS, and DFS were defined as in Study I. All patients had 
a minimum follow up of three years or until death.  
4.4 STUDY IV 
FCR data were used to collect MaSGCs that were registered in Finland during 
1953–2014. Selection of the patient cohort is illustrated in Figure 4. First, all 
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MaSGC topographies (n = 3055) were collected. The WHO classification (2005) 
was then applied to define the tumor morphology and non-salivary gland 
morphologies were excluded (n = 1328). Squamous cell carcinomas were also 
excluded, even though they can rarely have salivary gland morphologies. 
However, most of these carcinomas were metastases of other head and neck 
carcinomas. Considering mucoepidermoid carcinoma, this was coded under 
mucoepidermoid tumor (low or high grade) in the WHO tumor classification until 
1991. In the FCR, it was coded as squamous cell carcinoma until 2007, when the 
ICDO-3 coding became available. A search was conducted for the term 
“mucoepidermoid” from the original pathology reports, and 155 cases were found 
to be counted as SGCs. As mixed tumors were not included in the WHO 2005 
tumor classification, 30 pathology reports were randomly selected from a cohort 
of 195 mixed tumor samples found in the FCR data. These tumors were ex-
pleomorphic adenomas, as well as malignant myoepitheliomas; these were kept 
in the SGC cohort. Altogether, 1727 MaSGCs were used for SPC analyses. SPC was 
defined as any new cancer after SGC with histology. The follow-up time was 
counted from the date of SGC diagnosis to the SPC diagnosis, emigration from 
Finland, death, or December 31, 2014. In addition to FCR data on RT, a 
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Figure 4. Morphologic and histologic inclusion and exclusion criteria used in Study IV 
 
 38
4.5 STATISTICAL METHODS 
SPSS software was used for statistical analyses in Studies I, II, and III (Chicago, 
IL, USA, version 19.0 in Study I, 20.0 in Study II, 23.0 in Study III). Survival rates 
were calculated with the Kaplan-Meier method and survival functions were 
compared with the log-rank test. A p-value less than 0.05 was considered to be 
statistically significant.  
 
In Study II, the chi-squared test with exact p-values was used in the evaluation of 
differences in TLR staining in accordance with clinicopathological variables. For 
statistical purposes, tumors were divided into low (0 and 1) and high (2 and 3), 
and negative (0) and positive (1–3) categories.   
 
In Study III, Cox regression analysis was utilized in univariate associations of risk 
factors with OS, DSS, and DFS. The risk factors that were associated with OS, DSS, 
and DFS (p < 0.05 in univariate analysis) were used in a multivariable Cox 
regression model. To avoid multicollinearity problems, the stage was not included 
in the multivariable model with T class and neck metastases. Hazard ratios with 
95% confidence intervals were used in reporting the results.  
 
SIRs were counted in Study IV to determine the excess SPC risk for MaSGC 
patients. MaSGC patients were compared with the general Finnish population 
according to age, sex, and calendar period. This information was obtained from 
the Finnish cancer registry. SIRs were estimated based on the primary carcinoma 
age group, calendar period, tumor histology, patient RT status, and SPC site. 
Statistically smoothed SIRs for the SPCs as a function of the follow up after the 
diagnosis were assessed. Statistical language R (version 3.2.0) and the popEpi 
package (version 0.4.1) were utilized in all analyses.  
4.6 RESEARCH ETHICAL CONSIDERATIONS 
The protocols used in Studies I, II, and III were approved by the Institutional 
Research Ethics Board (Dnro 31/13/03/02/2010, 01 February 2010). The 
protocol in Study IV was approved by the National Institute for Health and 
Welfare, Finland (Dnro THL/263/5.05.00/2015). A research permit was obtained 
for each study from the Department of Otorhinolaryngology – Head and Neck 
Surgery at the Helsinki University Hospital. All studies were retrospective and 
consisted of examining hospital charts, histological specimens, or registry data, 
and had therefore no effect on the treatment of the patients included in these 




5.1 CHARACTERISTICS AND OUTCOME OF MAJOR AND     
MINOR SALIVARY GLAND ACC (STUDIES I AND III)   
The patient and tumor characteristics of 54 MaACC and 68 MiACC patients are 
described in Table 4. Most MaACCs (30/54, 56%) were of parotid origin and most 
MiACCs (41/68, 60%) were located in the oral cavity. Figure 5 illustrates the 
different locations of the MiACCs in the oral cavity.  
 
Table 4.  
Patient and tumor 
characteristics of 54 
major salivary gland 
ACCs and 68 minor 
salivary gland ACCs. 
Six tracheal tumors 
were not covered in 




n % n % 
Sex Male 28 52 29 43 
  Female 26 48 39 57 
Median age Years (range) 51 (22–80) 58 (24–88) 
Tumor site Parotid 30 56    
  Submandibular 22 41    
  Sublingual 2 4    
  Oral cavity    41 60 
  Paranasal cavities    6 9 
  Trachea    6 9 
  Nasopharynx    5 7 
  Oropharynx    3 4 
  Ear    4 6 
  Larynx    2 3 
  Esophagus     1 2 
T class T1 16 30 18 27 
  T2 12 22 12 18 
  T3 13 24 6 9 
  T4a 11 20 18 27 
  T4b 2 4 4 6 
  N/A 0 0 4 6 
N class N0 47 87 54 79 
  N1 5 9 1 2 
  N2a 0 0 1 2 
  N2b 1 2 1 2 
  N2c 0 0 1 2 
  N3 0 0 0 0 
  N/A 1 2 4 6 
Stage I 16 30 16 24 
  II 12 22 12 18 
  III 12 22 7 10 
  IVA 12 22 17 25 
  IVB 2 4 4 6 
  IVC 0 0 2 3 
  N/A 0 0 4 6 
Tumor size Median, mm (range) 23 (3–70) 21 (3–100) 
Growth  Cribriform 18 33 23 34 
pattern Tubular 6 11 15 22 
  Solid 6 11 4 6 
  Combination of the above 22 41 8 12 
  Not known 0 0 4 6 
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Figure 5. Location of 41 minor salivary gland ACCs in the oral 
cavity: 1. Hard palate (n = 15), 2. Floor of the mouth (n = 6), 3. 
Junction of the hard and soft palate (n = 5), 4. Mobile tongue (n = 5), 
5. Buccal mucosa (n = 3), 6. Gum (n = 3), 7. Upper lip (n = 3), 8. 
Mucous membrane of the oral cavity, not otherwise specified (n = 1). 
Courtesy of Ms. Terhi Liuhto.  
 
A lump at the tumor site was the most common first 
symptom in both MaACC (82%) and MiACC (28%) 
patients, followed by facial paresis (7.4%) and pain 
(7.4%) in MaACC and pain (18%) in MiACC patients. 
The duration of symptoms varied between 1–240 
months in both MaACC (median 12 months) and MiACC 
(median 6 months) patients. Six MaACC and three 
MiACC patients had a previous malignancy at the time of diagnosis (stomach 
carcinoma, laryngeal carcinoma, renal cell carcinoma, and myeloma in one case 
each, and prostate and thyroid carcinoma in two cases each).  
 
At diagnosis, ultrasound was performed on 70% and 16%, a neck CT scan on 24% 
and 58%, a chest CT scan on 22% and 31%, and neck MRI on 48% and 46% of the 
MaACC and MiACC patients, respectively. Fine needle aspiration had been 
performed on 77% and 12% of the MaACC and MiACC patients, respectively. 
 
The median tumor size was 23 mm for MaACCs and 21 mm for MiACCs. The 
tumor size could not be identified for nine MaACC and for 19 MiACC patients 
either from the clinical data or by re-evaluating the tumor samples. Cribriform 
was the most common growth pattern in both MaACC (33%) and MiACC (34%). 
In these studies, a minimum of 80% of the sample was required to consist of one 




Most patients (96% of MaACC and 94% of MiACC) were treated with curative 
intent. The primary treatment modality was surgery in 98% (MaACC) and 92% 
(MiACC) of the cases. In both patient groups, one patient received definitive RT 
with curative intent. Thirty-seven percent (MaACC) and 27% (MiACC) of the 
patients had neck dissection. For most patients (79% of MaACC and 82% of 
MiACC), neck dissection was prophylactic, i.e. they had no clinical evidence of 
locoregional metastases during diagnosis. Histologically confirmed neck 
metastases at the time of diagnosis were observed in 12% (MaACC) and 18% 




Postoperative RT for the primary tumor area was administered to 56% (MaACC) 
and 38% (MiACC) of the patients. The median dose was 60 Gy (range 50–66 in 
MaACC and 32–70 in MiACC). Within their oncological treatment, chemotherapy 
was offered to 4% (MaACC) and 8% (MiACC) of the patients. Two MaACC patients 
received palliative treatment, which was RT for the primary tumor area with doses 
of 30 and 55 Gy. Four MiACC patients received palliative treatment; three had 




Sixty-two percent (MaACC) and 48% (MiACC) of the patients treated with 
curative intent had either local or distant disease recurrence during follow up. For 
35% (MaACC) and 30% (MiACC) of the patients, the recurrence was in the 
primary tumor area. Regional metastases were observed in 8% (MaACC) and 13% 
(MiACC) of the patients, while distant metastases were observed in 50% (MaACC) 
and 34% (MiACC) of the patients. In most cases (48% in MaACC and 67% in 
MiACC), distant metastases appeared in the lungs, either alone or combined with 
another location. Other locations included the kidney, brain, liver, bone, and skin. 
For eight MaACC and three MiACC patients, information on the location of distant 
metastases was absent. The time point for the appearance of distant metastases 
varied between 1–156 months (median 46 months for MaACC and median 43 
months for MiACC patients) after the beginning of treatment. Most patients (72% 
in MaACC and 67% in MiACC) had disease recurrence (either locoregional or 
distant) within five years. For 28% (MaACC) and 27% (MiACC) of the patients, 
this occurred at least five years after the primary diagnosis. All MaACC patients 
(except one) and all MiACC patients (except two) had distant metastases within 
10 years after diagnosis. 
 
For patients treated with curative intent, the 5-year OS and DSS rates were, 
respectively, 69% and 71% (MaACC) and 70% and 79% (MiACC). The 10-year OS 
and DSS rates were, respectively, 54% and 62% (MaACC) and 42% and 52% 
(MiACC). At the end of follow up, 37% (MaACC) and 38% (MiACC) of the patients 
were alive with no evidence of disease, 6% (MaACC) and 9% (MiACC) were alive 
with disease, and 43% (MaACC) and 38% (MiACC) of the patients died of the 
disease. In both MaACC and MiACC, advanced T class, N class, and advanced 
stage had a negative effect on survival (Figure 6). Age over 45 years had a negative 
effect on survival in MaACC patients, while age under 65 years was associated with 
better OS in MiACC patients, as was female gender. For MiACC patients, positive 
neural invasion also had a negative effect on DFS. However, in multivariate Cox 
regression analysis, positive neural invasion was not an independent prognostic 
variable. In MaACC, neither perineural invasion nor gender affected survival. In 
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both groups, the appearance of distant metastases during follow up negatively 
affected OS and DSS (Figure 7). In contrast, locoregional metastases did not affect 
survival for MaACC patients, but were associated with poorer DSS in MiACC 
patients. Stage I MiACC patients had significantly better survival than patients 
with other disease stages. No stage I patients died due to disease, regardless of 
disease failures. In this patient group, there were three disease recurrences; two 
were local and both were located in the ear canal. The survival of stage II MiACC 
patients was significantly poorer than stage I patients, even though there were no 
significant differences in treatment. Regarding the patients who had distant 
metastases, 85% (MaACC) and 77% (MiACC) of the patients died due to disease, 
and this occurred within 12.6 (MaACC) and 15.3 (MiACC) years. In both groups, 
three patients with distant metastases were alive (follow-up time 58–149 months). 
 
Figure 6. Kaplan-Meier plot showing a significant difference in the disease-specific survival in 
major salivary gland carcinoma (A) and minor salivary gland carcinoma (B) patients with or 
without distant metastases.  
 
Figure 7. Kaplan-Meier plot showing a significant difference in the disease-specific survival of 
major salivary gland carcinoma (A) and minor salivary gland carcinoma (B) patients with T class 1 
and 2 compared with T class 3 and 4. 
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5.2 TLR5 AND 7 EXPRESSION IN MAJOR SALIVARY GLAND 
ACC (STUDY II) 
TLR5 and 7 expression patterns in MaACC were analyzed. TLR5 expression was 
mostly negative in normal salivary gland tissue. TLR5 was expressed in most 
primary tumor specimens (90%) and on cell membranes in all metastases. 
Nuclear and cytoplasmic expression was also seen. Areas with a cribriform growth 
pattern mostly showed cell membranous staining, whereas expression was more 
cytoplasmic in areas with solid and tubular growth patterns. Expression was 
mostly mild in both primary tumors (35%) and metastases (67%).  
 
TLR7 expression was usually negative in normal salivary gland tissue. It was 
mostly (50%) moderate in primary tumors and mostly mild (33%) or moderate 
(33%) in metastases. TLR7 expression was very heterogeneous. All tumors 
included strong positive areas and negative areas. Expression was detected on cell 
membranes in all primary tumors and metastases. In addition, primary tumors 
had some nuclear and cytoplasmic expression.  
 
TLR5 expression was lower in males (mean expression 0.89) than females (mean 
expression 1.69) (p = 0.022). TLR7 expression was lower in tumor samples with a 
solid growth pattern (mean expression 1.25) than in those with tubular and 
cribriform growth patterns (mean expression 2.21) (p = 0.003). There were no 
other correlations between clinical features and patient survival. Figure 8 









chemical expression of TLR5 
and 7 in MaACC. TLR5 
staining in ACC; cribriform 
area of the tumor (1, 2) and 
normal salivary gland tissue 
(3). TLR7 staining in ACC; 
cribriform area (4), solid 
area (5), and normal 
salivary gland tissue (6). 
Arrows indicate salivary 
gland tissue and the double 
arrow indicates nerves (c). 
Magnification ×200.  
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5.3 SPC IN MAJOR SALIVARY GLAND CANCERS (STUDY IV) 
Patient characteristics and the SPC risk are described in Table 5. Altogether, 1727 
MaSGC patients were registered in the FCR during 1953–2014. Most (73%) of the 
tumors were of parotid origin. The tumors were divided into 17 different 
morphologies, with ACC being the most common morphology (26%). SGC was the 
first cancer in most cases (92%). In total, 272 SPCs were detected, with a median 
follow up of 9 years (range 0–47). There was a 43% higher risk of developing SPC 
compared with the normal population (SIR 1.43, 95% CI: 1.24–1.63). The risk was 
similar in men and women. 
 
Table 5. Second primary cancer risk among patients with major salivary gland 
carcinoma. 
  










Sex      
Male 788 (45.6) 106 (13.4) 75 1,42 [1.16–1.71] 
Female 939 (54.4) 116 (12.4) 81 1,43 [1.19–1.72] 
Histology      
Adenocarcinoma 366 (21.2) 33 (9.0) 35 0,94 [0.64–1.31] 
Adenoid cystic carcinoma 455 (26.3) 59 (13.0) 46 1,29 [0.98–1.66] 
Mucoepidermoid carcinoma 221 (12.8) 28 (12.7) 19 1,5 [1.00–2.17] 
Acinic cell carcinoma 246 (14.2) 42 (17.1) 19 2,2 [1.59–2.98] 
14 other histologies 439 (25.4) 60 (13.7) 36 1,68 [1.28–2.16] 
Extent of disease      
Localized 998 (57.8) 158 (15.8) 111 1,42 [1.21–1.66] 
Locoregionally advanced/ 418 (24.2) 29 (6.9) 19 1,55 [1.04–2.22] 
Metastasized 
No information 311 (18.0) 35 (11.3) 26 1,35 [0.94–1.87] 
Age at diagnosis      
<55 671 (38.8) 90 (13.4) 55 1,63 [1.31–.2.00] 
55–69 622 (36.0) 85 (13.7) 66 1,28 [1.03–1.59] 
70–84 381 (22.1) 43 (11.3) 30 1,42 [1.02–1.91] 
>84  53 (3.1) 4 (7.5) 3 1,41 [0.38–3.60] 
Year of diagnosis*      
1953–69 274 (15.9) 17 (6.2) 11 1,49 [0.87–2.39] 
1970–84 361 (20.9) 27 (7.5) 21 1,27 [0.84–1.85] 
1985–99 471 (27.3) 41 (8.7) 27 1,49 [1.07–2.03] 
2000–14 621 (36.0) 40 (6.4) 28 1,44 [1.03–1.96] 
  *Follow-up time limited to 10 years to make calendar periods comparable 
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Figure 9 shows the SIR in follow up. The highest SPC risk was during the first 5 
years from SGC diagnosis (SIR 1.50). The risk was then closer to that in the normal 
population up to 19 years after diagnosis (SIR 1.25), but was again elevated 20 
years after diagnosis (SIR 1.81). Table 6 presents the risk for different SPC sites. 
The SPC risk was significantly elevated for thyroid cancer (SIR 5.12), melanoma 
of the skin (SIR 3.35), non-melanoma skin cancer (SIR 2.50), respiratory organ 
cancer (SIR 1.63), breast cancer (SIR 1.63), and cancer of the male genital organs 
(SIR 1.48). During the first five years after SGC diagnosis, the risk was higher for 
thyroid cancer (SIR 5.88, 95% CI: 1.21–17.20), melanoma (SIR 4.36, 95% CI: 
1.42–10.18), and non-melanoma skin cancers (SIR 6.73, 95% CI: 3.23–12.37). 
After 20 years from SGC diagnosis, the risk was higher for cancers of the 
respiratory organs (SIR 2.71, 95% CI: 1.17–5.34), male genital organs (SIR 2.81, 
95% CI: 1.03–6.12), and breasts (SIR 2.21, 95% CI: 1.01–4.19). Patients from all 
age groups had an elevated SPC risk. Carcinomas with all morphologies (except 
adenocarcinoma NOS) had an elevated SPC risk. Patients who had received RT 
did not have a significantly higher SPC risk compared with those who had not. 





























Table 6. Standardized incidence ratios of the second primary cancer risk in major 
salivary gland carcinoma patients in Finland during 1950–2014. 
 
Second cancer sites n SIR [95%CI] 
Brain, other central nervous system 8 2.00 [0.86–3.94] 
Eye -    
Thyroid gland 8 5.12 [2.21–10.08] 
Mouth, pharynx 7 2.33 [0.94–4.81] 
Respiratory organs  31 1.63 [1.11–2.31] 
    Lungs, trachea 26 1.45 [0.95–2.12] 
    Nose, sinuses 1 3.72 [0.09–20.74] 
    Larynx, epiglottis 3 3.29 [0.68–9.60] 
    Unspecified 1 2.37 [0.06–13.21] 
Breasts 33 1.63 [1.12–2.29] 
Digestive organs  34 0.82 [0.56–1.16] 
    Stomach 6 0.69 [0.25–1.50] 
    Small intestine 1 2.03 [0.05–11.32] 
    Colon 9 0.96 [0.44–1.82] 
    Rectum, rectosigmoid 6 0.99 [0.36–2.15] 
    Liver 2 0.86 [0.10–3.11] 
    Pancreas 4 0.62 [0.17–1.58] 
    Gallbladder, bile ducts 3 1.33 [0.27–3.88] 
    Salivary glands 1 3.25 [0.08–18.08] 
Female genital organs 13 1.21 [0.64–2.07] 
Male genital organs 31 1.48 [1.00–2.10] 
    Prostate  29 1.39 [0.93–1.99] 
    Testis 2 13.02 [1.58–47.02] 
Urinary organs 16 1.53 [0.88–2.49] 
Melanoma of the skin 12 3.35 [1.73–5.85] 
Skin, non–melanoma 13 2.50 [1.33–4.28] 
Other endocrine glands -    
Bone -    
Soft tissues 1 1.17 [0.03–6.49] 
Ill-defined or unknown 3 0.66 [0.14–1.94] 
Mesothelioma -    
Autonomic nervous system -    






Salivary gland malignancies are rare. The prognosis depends on the histological 
type and tumor characteristics. ACC is known to have a high distant metastasis 
rate and the prognosis is poor, especially when located in minor salivary glands. 
Treatment has not markedly changed over the years, with surgery and, in certain 
cases, postoperative RT being the standard treatment. Research on new molecular 
markers for diagnostics and target-specific therapies is currently active.  
 
To gain knowledge and to have an appropriate follow up for these patients, the 
behavioral pattern of ACC and secondary malignancies in SGCs were investigated 
in a Finnish population (Studies I, III, and IV). TLRs have been studied as 
prognostic markers in several cancers, and an attempt was made to clarify the role 
of TLR5 and 7 in ACC (Study II).  
 
6.1 GENERAL CHARACTERISTICS OF ACC PATIENTS 
(STUDIES I AND III)  
The present finding of most MaACCs being located in the parotid (56%) and most 
MiACCs in the oral cavity (60%), specifically in the palate (49%), is consistent with 
the existing literature 14, 17, 18, 38, 60. In MiACCs, all TNM stages were observed in the 
palatal tumors, with slightly more advanced stage distribution than in the other 
intraoral sites All nasopharyngeal and paranasal sinus tumors were of advanced 
stages. In a study by Shum et al. 67, palatal ACCs were mostly of high T3–T4 
classes. Other studies have also demonstrated that paranasal tumors are often 
found at an advanced stage and diagnosed late 101, 149. Tumors in the nasopharynx 
and paranasal sinuses may become symptomatic relatively late, being already in 
an advanced stage. In addition, palatal tumors may be more difficult to detect than 
in other intraoral locations, possibly explaining these findings.  
 
MaACC patients had a slight male predominance, but among MiACC patients 
there was a female predominance. Other studies have also shown gender 
variation, with a female predominance being more common 16, 66, 67, 150. Neural 
invasion was present in most patients, as has been noticed in other studies 151, 152. 
It appears that the clinical pattern of ACC in Finland does not significantly differ 




6.2 TREATMENT AND SURVIVAL IN ACC (STUDIES I AND III) 
Surgery has remained the main treatment modality in ACC. Neck dissection 
should always be performed in cases of clinically evident neck metastases. It is 
recommended to remove all lymph nodes in affected neck levels 50. In our series 
of MaACCs, neck dissection was performed on 37% of patients treated with 
curative intent. Neck dissection was elective with no clinically evident neck 
metastases in 79% of patients; of these patients, 12% had histologically proven 
neck metastases. Of the MiACC patients treated with curative intent, 42% had 
neck dissection, and 82% of these were elective. The occult neck metastasis rate 
has varied between 15–44% in Europe and the United States 84. It is not clear 
whether elective neck dissection should be performed in all ACC patients. Lee et 
al. 153 recommended it to achieve staging and prognostic information, even though 
there was no significant effect on survival in their study. Amit et al. 85 did not 
observe an effect on survival in their collaborative study, in which the occult 
metastasis rate was 17% and neck metastases mostly appeared in the ipsilateral 
neck levels I to III. 
 
Postoperative RT of primary tumors was administered to 56% (MaACC) and 38% 
(MiACC) of the patients. In other studies, postoperative RT has been shown to 
increase the survival of ACC patients in all stages, and particularly in the case of 
positive lymph nodes and positive margins 87, 88. IMRT has brought better local 
control and reduced side effects 86. Proton-beam therapy and raster-scanned 
carbon ion boost have shown promising results in advanced diseases 89, 90. CRT 
has also been shown to improve local control in some high-risk cases 19, 20.  
 
In both MaACCs and MiACCs treated with curative intent, factors that negatively 
affected survival included age over 45 (MaACC) and 65 (MiACC) years, advanced 
T class, advanced stage, and neck metastases during diagnosis. During follow up, 
the appearance of distant metastases negatively affected survival. In MiACCs, the 
appearance of locoregional metastases also negatively affected survival. 
Furthermore, no MiACC patients with stage I disease died due to ACC. In a study 
by Mücke et al. 154, stage I and II tumors did not have significant differences in 
prognosis. Amit et al. 22 found that age over 70 years, the presence of nodal and 
distant metastases, positive or close margins, and a sinonasal origin were 
prognostic markers for poorer survival. Similarly to our results, others have also 
shown that T class, N class, and stage affect survival 150, 154, 155.  
 
In this study of MiACCs, the only stage I patients who had treatment failure had 
tumors located in the ear or in the oropharynx. No disease recurrences appeared 
in oral cavity tumors. The assumption is that disease-free surgical margins are 
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more easily achieved with these small tumors located in the oral cavity than in the 
oropharynx or in the ear, which are locations with a more challenging anatomy. 
In contrast, two other patients with advanced-stage tumors in the ear did not have 
disease failures, but were treated more aggressively with postoperative RT. ACC 
patients with tumors in this challenging location could possibly benefit from more 
aggressive treatment, even with stage I disease. This might also be feasible for 
MiACC patients with stage II tumors in the oral cavity, as these patients appear to 
have a poor outcome and a high percentage of disease failures.  
 
In MiACCs, female gender was also associated with improved OS. In our study, 
there was no gender correlation with survival in MaACCs. However, while 
Ellington et al. 81 also found that females had a better prognosis, Marcinow et al. 
101 observed that female gender predicted a poorer outcome. The finding of 
improved survival might also reflect the higher life expectancy of women in 
general.  
 
Neural invasion did not correlate with survival in MaACC. While neural invasion 
negatively affected DFS in MiACC, no correlation was found with local or 
locoregional recurrences. Some studies have demonstrated that perineural 
invasion is associated with local recurrence and margin involvement, but not with 
survival 66, 100. However, many studies have also found a correlation between 
perineural invasion and poorer survival 23, 100, 101, 156. ACC is thought to metastasize 
mainly hematogenously, but neurotropism is still typical of ACC 60.  
 
In this study of patients treated with curative intent, 62% (MaACC) and 48% 
(MiACC) of the patients had disease recurrence or the appearance of distant 
metastases. Bradley et al. 157 also found that approximately 60% of patients will 
suffer from disease recurrence. Recurrence in the primary tumor area was 
observed in 35% (MaACC) and 23% (MiACC) of the patients in our studies. In a 
MiACC study by He et al. 23, the primary metastasis rate was 40%. In our series, 
8% (MaACC) and 9% (MiACC) of the patients had neck metastases during follow 
up. This is consistent with other studies on neck metastases, which have been 
reported to occur in 3–16% of patients 23, 84. 
 
Distant metastases are thought to be the main reason for poor survival rates. They 
were observed in 50% (MaACC) and 67% (MiACC) of the patients. Most distant 
metastases appeared within 10 years of treatment. In other studies, the median 
time to appearance of distant metastases has varied from 1–9 years 12, 14, 152, 158, 159. 
In the literature, distant metastases are reported to appear in 20–55% of ACCs 17, 
22, 67, 91, 160. The most common location for distant metastases is the lungs, 
consistent with our studies. Lung metastases are often not solitary. Routine 
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thoracotomy is not advised, as metastases can remain relatively stable for months. 
17, 91 According to Girelli et al. 21, lung metastasectomy should be considered to 
achieve local control if complete metastasis removal is possible and pulmonary 
metastases appear more than 36 months after primary treatment. Whether 
incomplete lung resection of lung metastases provides symptomatic benefit is not 
clear 17, 91.  
 
Otherwise, the options for patients with metastatic disease are supportive care and 
observation, palliative systemic therapy, or participation in clinical trials 60. In our 
series of MaACC, only two patients received palliative RT, with a subsequent 
survival of five and 12 months. Choi et al. 151 found no significant difference in 
survival between patients treated with palliative chemotherapy after a relapse 
compared with patients receiving only supportive care. The median survival after 
recurrence was 77 months 151.  
 
The solid growth pattern is related to a higher metastatic rate and poorer survival. 
According to WHO, tumors consisting of more than 30% solid pattern have more 
aggressive behavior 10, 26. He et al. 23 found the solid pattern to be an independent 
prognostic marker in MiACC. Others have found the solid pattern to increase the 
distant metastasis risk 12, 22, 96. In this study, a correlation between the solid type 
and survival was not found in MiACC. In MaACC, while the solid type had a slight 
negative association with survival, the results were not statistically significant. 
 
In our studies, the 5-year OS and DSS rates were, respectively, 69% and 71% 
(MaACC) and 70% and 79% (MiACC). The 10-year OS and DSS rates were, 
respectively, 54% and 62% (MaACC) and 42% and 52% (MiACC). While the 
difference in 5-year survival was not significant, patients with MiACCs appear to 
have a poorer prognosis for long-term survival. In a study by Ellington et al. 81, 
MiACC patients had decreased survival compared with MaACC patients. 
Similarly, in a Danish series, the 5-year OS and DFS rates were 80% and 72%, 
respectively, while the 10-year rates were 58% and 60%, respectively 14. In 
addition, in a study by Amit et al. 22, the 5-year OS and DSS rates were 76% and 
80%, respectively. As most distant metastases appear within 10 years, it might be 
reasonable to prolong routine follow-up imaging for an extended time period. 
6.3 TLRS IN SALIVARY GLAND CANCERS (STUDY II) 
In this study, TLR5 and 7 expression was found in both primary ACC tumors and 
metastases. Expression varied from negative to strong within the same tumor. 
Different expression patterns (nuclear, cytoplasmic, and membranous) were also 
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usually observed within the same tumor sample. Both TLRs were mostly negative 
on normal salivary gland tissue. Low TLR5 and 7 immunopositivity correlated 
with male gender and a solid growth pattern, respectively. These TLRs did not 
correlate with disease recurrence or patient survival, and they are therefore not 
suitable as clinical prognostic markers in ACC. 
 
TLR5 has previously been described in salivary gland adenocarcinomas. That 
study suggested that bacterial flagellin promotes invasion and migration through 
a TLR5-induced pathway 129. TLR5 was also investigated in OTSCC, where high 
immunopositivity correlated with advanced age, female gender and DSS, and it 
was an independent predictor of disease recurrence and mortality 170. Similar to 
our study, low TLR5 staining intensity correlated with male gender. In 
contradiction, in early stage OTSCC, Mäkinen et al. 118 found negative or mild 
TLR5 staining to predict poorer DSS. In HPV-positive OPSCC, high TLR5 
expression was possibly related to a poor prognosis 123. In our study on ACC, TLR5 
was mainly expressed on plasma membranes, although some subcellular 
positivity was additionally seen. Other studies have also shown TLR5 expression 
on plasma membranes and additionally in cytoplasm 116, 122, 161. Further research is 
necessary to understand the role of TLR5 in SGCs. 
 
To our knowledge, TLR7 has not previously been studied in salivary gland tumors. 
In juvenile angiofibroma, TLR7 was expressed on cell membranes but had no 
clinical correlations 127. In OPSCC, HPV-positive cancers showed high TLR7 
positivity and low TLR5 positivity. These tumors are known to have better 
sensitivity to RT 122. Low TLR7 expression was possibly related to the poor 
prognosis in this patient group 123. In another OPSCC study, low tumor cell TLR7 
expression as well as high stromal TLR7 expression correlated with improved 
survival 162. Another study demonstrated high TLR7 and low TLR5 expression in 
p16-positive OPSCC in vivo and in vitro. In addition, TLR7 and 9 expression 
correlated with the HPV status in vivo 122. TLR9 has also been studied in 
mucoepidermoid carcinoma, where low TLR9 expression correlated with an 
advanced disease stage and a poor prognosis 128. In lung cancer, TLR7 correlates 
with resistance to neoadjuvant chemotherapy and a poor clinical outcome 163. In 
this study, TLR7 expression was detected on plasma membranes in all tumor 
samples. TLR7 is usually expressed intracellularly in endosomes, lysosomes, and 
endoplasmic reticulum, and it recognizes viral single-stranded RNA 24, 104, 161. 
Jouhi et al. 122 demonstrated TLR7 expression on the nuclear membrane and in 
nuclei. TLR7 expression on the plasma membrane remains to be elucidated. 
 
In this study, low TLR7 expression was found to correlate with a solid growth 
pattern. A solid growth pattern has a poorer prognosis and the highest metastasis 
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rate 12. Similarly, in our series, a solid growth pattern correlated with the 
appearance of neck metastases, but not with survival.  
6.4 SPCS IN SALIVARY GLAND CANCERS (STUDY IV) 
The long-term outcome of SGC patients depends on histology, grade, and location, 
among other factors. Many patients live long after SGC treatment, and knowing 
the risk of SPC is important when considering their follow up. In head and neck 
cancers, routine follow up has not been clearly shown to prolong survival, even 
though it helps to detect recurrences and SPCs earlier 164. SPCs have an important 
impact on survival in some cancers, for example in Hodgkin’s lymphoma 130. The 
risk of SPC in any cancer patients is estimated to be approximately 14% higher 
than would have been expected in the general Surveillance, Epidemiology, and 
End Results (SEER) population in the United States 25. Some SPCs are probably 
treatment-related (such as the late effects of RT), and some are caused by the 
influence of lifestyle factors (such as tobacco smoking or environmental 
exposures) 25. Syndromes and a mixture of different influences such as gene–
environment and treatment and lifestyle interactions may also be the cause of SPC 
131.  
 
In patients with HNSCC, SPCs usually appear in the head and neck area, lungs, 
esophagus, and colorectum. Alcohol consumption and tobacco smoking are the 
same risk factors as for the primary cancer. 137, 138, 165 In a large study with 13 cancer 
registries, Chuang et al. 165 showed HNSCC patients to have a 36% increase in the 
20-year cumulative risk of SPCs. The risk was highest in the lungs, oral cavity, 
pharynx, esophagus, and larynx. 
 
In this study, the SPC risk for MaSGC patients was investigated over a 60-year 
period in Finland. It was found that these patients had a 43% higher risk for an 
SPC than the cancer risk in the general population. The risk is higher than in 
cancer patients in general in Finland (www.cancer.fi) and in HNSCC patients in a 
study by Chuang et al. 165. In this study, the SPC risk after SGC was found to be 
highest for thyroid cancer. The risk of melanoma of the skin, other skin cancers, 
breast cancer, cancer of the respiratory organs, and cancer of the male genital 
organs was also significantly increased.  
 
Few studies exist on the SPC risk of SGC patients. Most of the existing studies have 
focused on the risk of second breast cancer appearing after SGC. Similar to our 
observations, others have shown that SGC patients have a higher risk of 
developing breast cancer, with SIRs ranging between 2.3–4.8 141-144. However, in 
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other studies, no association has been found between these two cancers 145-147. 
There are some histological similarities between SGCs and certain breast cancers. 
Both cancers have an adenoid-cystic cell type and, furthermore, epithelial-
myoepithelial carcinoma of the salivary gland and adenomyoepithelioma of the 
breasts also share similarities. It is unknown whether common etiological factors 
might explain this relationship. 142  
 
Similar to our findings, Biggar et al. 145 demonstrated an increased respiratory SPC 
risk in men. Contrary to our findings, however, they also found an increased 
ovarian SPC risk 145. In a series of 825 SGC patients, Prior et al. 141 observed an 
increased breast and bronchus SPC risk in women and prostate and skin SPC risk 
in men. These findings are consistent with our observation of an increased risk of 
breast cancer, melanoma and non-melanoma skin cancer, and cancer of the 
respiratory organs and male genital organs. In contrast to our observations, der 
Maur et al. 144 found that the oral/oropharyngeal SPC risk is higher after SGC. 
However, their study also included minor salivary glands and both benign and 
malignant tumors 144. Kwon et al. 166 compared the incidence of SPCs in 184 SGC 
patients with a number of newly developed cancers in 200 healthy controls and 
found no significant difference in cumulative SPC incidence between these groups. 
However, the sample size was quite limited.  
 
There have only been two previous studies on the SPC risk in MaSGC patients. 
Megwalu and Shin 146 found a 24% higher overall SPC risk in their SEER database 
study with 15,572 MaSGC patients. The risk was significantly increased for cancers 
of the salivary glands (SIR 9.97), oral cavity (SIR 3.48), thyroid (SIR 2.66), lungs 
and bronchi (SIR 1.60), and kidney (SIR 1.68) 146. Similar to the findings in this 
study, they observed the thyroid to be among the three sites with highest risk. In 
their study on 498 MaSGC patients, Spitz et al. 147 found an elevated risk for skin 
cancer in men, with a relative risk of 3.83 (95% CI: 1.28–11.49). In this study, an 
increased risk for melanoma and non-melanoma skin cancers in MaSGC patients 
was also found, and men had a higher risk than women. The risk was high only 
during the first five years after diagnosis. As these cancers can be visible and thus 
detected by clinical examination, it is assumed that they were more effectively 
diagnosed during the close surveillance period following cancer management. 
However, Spitz et al. 148 reported that men who had primary skin cancer had an 
estimated odds ratio of 13.7 (95% CI: 4.17–44.97) for developing MaSGC. Others 
have also shown that skin melanoma and non-melanoma skin cancer patients 
have an elevated risk of developing SGC. It has been hypothesized that a genetic 
link or shared risk factors (e.g., UV radiation) exist for these cancers. 167, 168 There 
is also a biological relationship between cutaneous and major salivary gland 
neoplasms, with similarities in their embryologic derivation, histogenesis, and 
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histological composition. They are both formed from ectoderm and manifest 
similar stages in embryologic development. 169  
 
In the study by Megwalu and Shin 146, the SPC risk remained high up to 10 years 
after MaSGC diagnosis. In this study, it was found that the SPC risk was higher 
during the first few years after diagnosis, but between 5 and 10 years, this risk did 
not differ from that of the general population. The risk then started to rise again, 
with the highest risk being at 20 years after SGC diagnosis. An increased thyroid 
cancer risk was demonstrated from the start of follow up to 20 years after SGC 
diagnosis. It is assumed that some overdiagnosis may occur, particularly in cases 
of thyroid and skin cancer, when patients are under careful follow up. However, 
the fact that the thyroid cancer risk remained elevated up to 20 years after SGC 
diagnosis does not suggest surveillance bias but more likely indicates that RT in 
the neck region increases the risk of thyroid cancer. The finding of an elevated 
thyroid SPC risk among patients who received RT supports this possibility, even 
though RT was not observed to significantly increase the overall SPC risk 
compared with SGC patients who did not receive RT. In the study by Megwalu and 
Shin 146, RT treatment increased the SPC risk for thyroid, larynx, and 
lungs/bronchi, but had no correlation with the development of oral SPC. In the 
SEER registry study with a series of 190,468 HNSCC patients, Shaaban et al. 138 
did not observe an increase in SPC risk following RT. Our finding of an elevated 
SPC risk in MaSGC patients even after 20 years after diagnosis should be 
recognized when planning the follow up for these patients.  
6.5 LIMITATIONS AND STRENGTHS OF THE THESIS 
In Studies I and III, the hospital records of patients diagnosed with ACC over a 
period of 35–38 years were retrospectively reviewed. Most of the needed data were 
available. However, particularly in the older charts, some information was lacking 
in single cases. Some parameters, such as surgical margins, were not sufficiently 
reported to enable relevant conclusions, and the amount of paraffin-embedded 
tissue was also insufficient for the corresponding cases to collect this information. 
Even though treatment modalities have not significantly changed, there are still 
variations in treatment approaches, which might affect the survival data in 
retrospective studies. However, follow-up data were available for all patients 
except one, and a minimum follow-up time of 5 years and 3 years or until death in 
MaACC and MiACC studies, respectively, was obtained. Studies I and II included 
patients from only one academic center representing approximately one third of 
the Finnish population. The number of patients (54 in Study I and 68 in Study III) 




For immunohistological evaluation (Study II), 34 MaACC samples were available, 
which is a limited series. However, this is a common problem with rare diseases, 
and multi-institutional studies are warranted in order to draw even more reliable 
conclusions. Some of the samples were also small, which made the assessment of 
the staining intensity difficult. Determining the percentage of positive staining is 
subjective and thus prone to bias. However, two independent researchers 
performed the scoring, which reduced this bias.  
 
In Study IV, all histological types of MaSGCs were included and FCR data over 60 
years were used to investigate the appearance of SPCs in a nationwide series. This 
long time period is a strength, and practically complete follow-up data including 
causes of death were available. However, there was no information on smoking or 
alcohol consumption. Another limitation in Study IV is that the histologic 
classification of SGCs has changed over the years. This might have led to the 
missing of some cases that would currently be classified as SGCs. In addition, 
diagnostic methods have significantly improved and classification has become 
more specific. In 1972, there were only five SGC categories, whereas the 2017 
WHO classification has 22 SGC categories. An attempt was made to gather all 
possible cases with changed nomenclature and to exclude the cases with missing 
classification data to minimize this bias. 
6.6 FUTURE PERSPECTIVES FOR ACC RESEARCH 
Finding novel treatment approaches for recurrent ACC remains an important 
objective for future research. ACCs are rather rare and challenging to manage, and 
the development of more efficient treatment protocols thus requires multicenter 
collaboration. Patients with stage II tumors are a specific group to be included in 
such trials. The present study suggests evaluating the effect of prolonged follow 
up on the long-term outcome in this patient population. Larger patient cohorts 
would enable the validation of potential prognostic and predictive markers. This 
would also allow the inclusion of patients in need of palliative therapy in clinical 
trials. As their tumors and previous treatment are heterogeneous, these factors 
should be carefully considered when assessing data and study conclusions.  
 
Proton-beam therapy and raster-scanned carbon ion boost combined with IMRT 
have shown promising results in advanced disease. Similarly, in the Helsinki 
University Hospital setting, it would be interesting to examine the role of boron 
neutron capture therapy. Future studies might clarify the role of these treatment 




Efforts towards the development of targeted molecular therapy are currently in 
progress. However, further molecular analysis studies are needed. In the future, 
genome sequencing may be useful in identifying critical molecular alterations and 








1. More than half of MaACC and MiACC patients developed distant metastases 
within 10 years in the present studies and therefore, an extended follow-up time 
is recommended for this patient population. Older age, advanced T class, 
advanced stage, neck metastases at diagnosis, and distant metastases during 
follow up negatively affected survival in both MaACC and MiACC patient groups. 
In addition, the occurrence of locoregional metastases had a negative effect on 
survival in MiACC patients. Furthermore, they also appear to have worse 10-year 
survival compared with MaACC patients. MiACC patients with stage I disease had 
a significantly better prognosis than stage II patients. Stage II patients should be 
considered as having clearly advanced disease, and a more aggressive treatment 
approach thus needs to be considered for this subgroup. 
 
2. TLR5 and 7 expression was observed in MaACC specimens. The intensity and 
pattern of expression were extremely heterogeneous, reflecting the histological 
diversity of ACCs. Low TLR5 positivity correlated with male gender and low TLR7 
positivity with a solid growth pattern. There was no correlation between 
expression and survival.  
 
3. SGC patients appeared to have a significantly increased risk for the 
development of SPC, especially thyroid cancer, compared with the cancer risk of 
the general population. This risk remained high even after 20 years after 
diagnosis, and an extended follow-up time regarding this issue in primary health 
care is therefore recommended, as detecting the SPCs early may prolong long-
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